

# BEACON Annual Report 2022



**12** Years  
A LIGHT OF HOPE

LEAD THE FIGHT, BEAT THE CANCER  
THROUGH TECHNOLOGY & EXPERTISE

**BEACON**<sup>®</sup>  
*Light for life*





## Our Vision

---

To be regarded and recognized as one of the most value-driven pharmaceutical companies in the world.

## Our Mission


---

To improve the quality of human life by providing innovative pharmaceutical products developed through continuous research and development ensuring stakeholders satisfaction.

## Core Values

---

- Committed to quality in all our activities.
- Trustworthy relationship with customer.
- Respect to other.
- Work as a team.
- Believe in winning.
- Encourage innovative ideas.
- Corporate Social Responsibility.



**Corporate Office**  
**BEACON Business Centre**  
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223

# Letter of Transmittal

---

28 November 2022

All the Shareholders  
Bangladesh Securities and Exchange Commission  
Registrar of Joint Stock Companies & Firms  
Dhaka Stock Exchange Limited  
Chittagong Stock Exchange Limited

Subject: Annual Report for the year ended 30 June 2022.

Dear Sir(s),

We are pleased to present before you the Annual Report of **Beacon Pharmaceuticals Limited** for the year ended 30 June 2022 together with the Audited Financial Statements, Report of the Board of Directors and Auditors' Report thereon for your information and reference.

The Proxy Form with Attendance Slip is attached at the end of the Annual Report for your use. In case of appointing a proxy, please complete the Proxy Form and submit it to our corporate office at least 72 hours before the scheduled meeting time. This will be our utmost pleasure to welcome you to the 21<sup>st</sup> AGM of the Company.

Truly yours,



**Khalilur Rahman FCS**  
Company Secretary (Acting)

# MILESTONES



Beacon Chronic Care has launched breakthrough molecule in diabetes management, Empagliflozin-Linagliptin Fixed Dose Combination (FDC) in the brand name "Sinjard L" as 1st time launch in Bangladesh in 2022, First oral erythropoietic drug introduction and nationwide mass awareness creation on Thalassemia.

# CORPORATE OVERVIEW



## Stock Exchange Listing

- Dhaka Stock Exchange Limited
- Chittagong Stock Exchange Limited



## Business Line

Manufacturing and Marketing of  
Pharmaceutical Products



## Major Product Segments

General, Oncology,  
Biotech & Chronic Care



## Authorized Capital

BDT 3,000 Million



## Paid-up Capital

BDT 2,310 Million



## Number of Shares Outstanding

231 Million



## Number Employees

3,691



## Number of Shareholders

8,315



## Major Sister Concerns

- Beacon Point Limited
- Beacon Medicare Limited
- Beacon Power Systems Limited
- Beacon Developments Limited
- Beacon Cephalosporin Limited
- Beacon Business Solutions limited
- EREBA Capsules Limited



## Debut Trading Date

12<sup>th</sup> August, 2010

# BEACON AT A GLANCE





**Beacon Pharmaceuticals Limited** is a leading Pharmaceutical Company of Bangladesh in respect of its high-tech products like anticancer and cardiovascular portfolio. Beacon, a public limited company listed with Dhaka and Chittagong Stock Exchange, was incorporated on 12<sup>th</sup> September, 2001 as a private limited company with the Registrar of Joint Stock Companies and Firms, Dhaka, Bangladesh under the Companies Act 1994 and subsequently converted into a Public Limited Company on 2010.

Since its inception, Beacon is relentlessly working with a mission to improve the quality of human life by providing innovative and reliable pharmaceutical products through continuous research and development by ensuring stakeholder satisfaction with the aim to be one of the most value driven Pharmaceutical Companies of the World.

Beacon is a very popular name in the Pharmaceuticals Industry of Bangladesh due to its high quality products of Anticancer, Cardiovascular, Gastrointestinal, Antibiotics, Anti-Coagulants, Protein Supplements, Muscle relaxant, Anti-histamine, Analgesics and NSAIDS etc.

The Plant is situated at Bhaluka, Mymensingh, Bangladesh on a piece of land of 30 Acres with the covered area of more than 2,00,000 sft. The initial cost of the project stands at more than US\$.50.00 Million. This manufacturing complex of Beacon has been engineered by European consultants in order to be one of the finest facilities in the Country. It has been designed to conform to world standards like US-FDA, UK-MHRA, TGA-Australia and WHO -cGMP.

# FIND INSIDE

## CORPORATE MANAGEMENT

12-29

1. Corporate Directory	14-15
2. Biography of Board of Directors, Company Secretary, CFO and HIA	16-19
3. Board Committees	20-21
4. Message from the Chairman	22-23
5. Managing Director's Overview	24-27
6. Our Strength	28
7. Performance Highlights	29

## CARING GLOBAL CANCER PATIENTS- A Decade of Innovation & Prestige for Beacon and Bangladesh

32-33

## DR, ACR & NRC REPORT

37-49

1. Directors' Report to the Shareholders	37-45
2. Audit Committee Report	46-47
3. Nomination and Remuneration Committee Report	48-49

## DECLARATION BY CEO AND CFO

50

# FIND INSIDE

## CORPORATE GOVERNANCE

53-75

1. A Guideline of Transparency and Accountability	53
2. Status of Compliance with the Corporate Governance Guideline (CGC)	54-74
3. Certificate on Compliance of Corporate Governance	75

## DIRECTORS' RESPONSIBILITIES

76-77

Directors' Responsibilities for the Financial Statements	77
--	----

## FINANCIAL STATEMENTS

80-129

1. Independent Auditors' Report	82-86
2. Statement of Financial Position	87
3. Statement of Profit & Loss and Other Comprehensive Income	88
4. Statement of Changes in Equity	89
5. Statement of Cash Flows	90
6. Notes to the Financial Statements	91-127
7. Schedule of Fixed Assets	128
8. Defferred Tax Schedule	129

## ADDITIONAL INFORMATION

130-135

1. Notice of 21 <sup>st</sup> Annual General Meeting	130-131
2. Photos of 20 <sup>th</sup> Annual General Meeting	132
3. Proxy Form & Attendance Slip	135

# CORPORATE MANAGEMENT

---





# Corporate Directory

## BOARD OF DIRECTORS

### Chairman

- Mrs. Nurun Nahar Karim

### Managing Director

- Mr. Mohammad Ebadul Karim

### Directors

- Mr. Md. Niazul Karim
- Major M.A Hussain (Retd.)
- Mr. Mohammad Sanaullah FCS

## COMPANY SECRETARY (Acting)

- Mr. Khalilur Rahman FCS

## CHIEF FINANCIAL OFFICER (CFO)

- Mr. Md. Abdul Haque Sarder FCS, FCA

## HEAD OF INTERNAL AUDIT

- Mr. Md. Jalal Uddin FCA, SVP (Internal Audit)

## AUDIT COMMITTEE

- Mr. Mohammad Sanaullah FCS, Chairman
- Mr. Md. Niazul Karim, Member
- Major M.A Hussain (Retd.), Member
- Mr. Khalilur Rahman FCS, Board Secretary

## NOMINATION AND REMUNERATION COMMITTEE

- Major M.A Hussain (Retd.), Chairman
- Mr. Mohammad Sanaullah FCS, Member
- Mr. Md. Niazul Karim, Member
- Mr. Khalilur Rahman FCS, Board Secretary

## EXECUTIVE MANAGEMENT COMMITTEE

- Mr. Mohammad Ebadul Karim, Managing Director
- Mr. Md. Niazul Karim, Director
- Ms. Risana Karim, Executive Director
- Mr. Ulfat Karim, Executive Director
- Mr. Md. Abdul Haque Sarder FCS, FCA, Director (Finance & Accounts) & CFO
- Mr. Monjurul Alam, Director (Business Development)
- Ms. Najmun Nahar Rahman, Director (Plant Operations)
- Mr. Md. Golam Rabbani, Director (Plant Operations)
- Mr. Md. Anisur Rahman Khan, EVP (HR & Administration)
- Mr. Md. Abdus Salam FCA, Financial Advisor

## STATUTORY AUDITORS

**M/S. Toha Khan Zaman & Co.**  
Chartered Accountants  
House No-817 (First Floor), Road No-4  
Baitul Aman Housing Society, Adabor, Dhaka-1207

## CORPORATE GOVERNANCE COMPLIANCE AUDITOR

**Poddar & Associates**  
Cost and Management Accountants  
333/1 (New 8/1) Segun Bagicha (2nd & 3rd Floor), Dhaka-1223.

## LISTING

1. Dhaka Stock Exchange Limited
2. Chittagong Stock Exchange Limited

## REGISTERED OFFICE

**Beacon Pharmaceuticals Limited**  
Kathali, Bhaluka, Mymensingh, Bangladesh.

## CORPORATE OFFICE

**Beacon Business Centre**  
9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223  
Tel: +880-2-57165371-6, Fax: +880-2-57165379-80  
E-mail: beacon@beaconpharma.com.bd  
Website: www.beaconpharma.com

## FACTORY

Kathali, Bhaluka, Mymensingh.

## MAIN BANKER

- Janata Bank Limited
- Sonali Bank Limited
- Agrani Bank Limited
- Rupali Bank Limited
- Dutch Bangla Bank Limited
- First Security Islami Bank Limited
- Commercial Bank of Ceylon (PLC)
- United Commercial Bank Limited
- Eastern Bank Limited
- Standard Chartered Bank Limited
- Social Islami Bank Limited
- Bank Asia Limited
- BRAC Bank Limited
- Shahjalal Islami Bank Limited

# Biography of Board of Directors, Company Secretary, CFO and HIA

## BOARD OF DIRECTORS

### Chairman

- Mrs. Nurun Nahar Karim

### Managing Director

- Mr. Mohammad Ebadul Karim

### Directors

- Mr. Md. Niazul Karim
- Major M.A Hussain (Retd.)
- Mr. Mohammad Sanaullah FCS

## COMPANY SECRETARY (Acting)

- Mr. Khalilur Rahman FCS

## CHIEF FINANCIAL OFFICER (CFO)

- Mr. Md. Abdul Haque Sarder FCS, FCA

## HEAD OF INTERNAL AUDIT

- Mr. Md. Jalal Uddin FCA, SVP (Internal Audit)





## Mrs. Nurun Nahar Karim

Chairman

Mrs. Nurun Nahar Karim obtained her Master of Social Sciences degree (Pol. Science) from the University of Dhaka. She is the wife of Mr. Mohammad Ebadul Karim. She brings significant industry experience and management insight to the board. With her visionary leadership and executive oversight experience, she has been fueling the company's strategic growth. She is the Chairman of Beacon Pharmaceuticals Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Beacon Oncology Limited, Mujibunnessa Medical College & Hospital Limited. She is also the Director of Beacon Developments Limited, Beacon Point Limited, Beacon Economic Zone Limited, Beacon Medicare Limited, Beacon Cephalosporin Limited, Beacon Power Systems Limited, Beacon Business Solutions Limited and Kohinoor Chemical Co. (BD) Limited.



## Mr. Mohammad Ebadul Karim

Managing Director

Mr. Mohammad Ebadul Karim entered into the realm of business horizon after completion of his graduation. By virtue of his entrepreneurial skill and sound management capability accompanied with vast experience and farsighted vision, he has been running a number of business enterprises very successfully. He is the Managing Director of Beacon Pharmaceuticals Limited, Beacon Developments Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Mujibunnessa Medical College & Hospital Limited, Beacon Oncology Limited and Chairman of Beacon Power Systems Limited, Beacon Point Limited, Beacon Medicare Limited, Beacon Cephalosporin Limited, EREBA Capsules Limited, Beacon Economic Zone Limited and Beacon Business Solutions Limited. He is also the Director of Kohinoor Chemicals Co. (BD) Limited. He has travelled many countries of the world for business purposes and won many awards home and abroad.



## Mr. Md. Niazul Karim

Director

Mr. Md. Niazul Karim, son of Mr. Mohammad Ebadul Karim holds a Bachelor's degree in Business Administration from Independent University of Bangladesh (IUB). Right after completing his graduation, he was actively involved in the business. He contributes to the board through his prudent decision outcomes and solid understanding of industrial operations. Presently he is acting as the Director of Beacon Pharmaceuticals Limited, Beacon Developments Limited, Beacon Cephalosporin Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Mujibunnessa Medical College & Hospital Limited, Beacon Oncology Limited, Beacon Power Systems Limited, Beacon Business Solutions Limited and Managing Director of Beacon Point Limited, Beacon Medicare Limited, Beacon Economic Zone Limited.



## Major M. A. Hussain (Retd.)

Independent Director

Major M.A Hussain got the opportunity to join Army in 1968 as an Officer Cadet when he was a student of Department of History, Dhaka University. After completing training from Military Academy in Kabul, he got Commission in 1970. His first posting was in Kashmir (POK). He served in Bangladesh Army as a Major in 1976. He also served as DAAG (Deputy Asst. Adjutant General) in 24 divisional HQ. He joined Bangladesh Bank on deputation in 1985 and got absorbed having seniority from the date of commission. Major Hussain retired from Bangladesh Bank as a General Manager in 2008. The diverse set of experiences he attained throughout his career provides precious strategy guidance to the board. He is the Chairman of the NRC.



## Mr. Mohammad Sanaullah FCS

Independent Director

Joined the Board on June 29, 2022

Mr. Mohammad Sanaullah is the CEO and Lead Consultant of Mohammad Sanaullah & Associates. An Independent Professional Firm of Chartered Secretaries and Management Consultants.

Mr. Sanaullah served as Corporate Affairs Director, Head of Human Resources and Company Secretary of Singer Bangladesh Limited (a reputed MNC), with over 34 years' exposures in business, corporate management and governance.

Mohammad Sanaullah served three times President at the Institute of Chartered Secretaries of Bangladesh (ICSB), Nominee Director at Singer Bangladesh Limited and Non- Executive Director at Bangladesh Institute of Capital Market (BICM), Executive Member at Corporate Secretaries International Association (CSIA) Headquarter in Hong Kong - A Global Voice of Governance. He is a certified trainer on Corporate Governance - Board Leadership of the Global Corporate Governance Forum (GCGF) of International Finance Corporation (IFC).

Mr. Sanaullah also served as an Independent Director (appointed by the BSEC) and Chairman Audit Committee on the Board of Fareast Life Insurance Company Limited and Fu-Wang Foods Limited. He is one of the founding Vice President of the Bangladesh Accounting Association (BAA). Currently, He is the Member of the Advisory Board of Bangladesh Accounting Association (BAA).

A Fellow Member (FCS) of the Institute of Chartered Secretaries of Bangladesh (ICSB), He also did Post Graduate Diploma in Personnel Management from BMDC now Bangladesh Institute of Management (BIM).

Mohammad Sanaullah completed his Graduation with Honors in Accounting and Post Graduation in Accounting from the, University of Dhaka. He also did MBA in Marketing. He has served as MBA faculty for more than 20 years in the leading Universities of the country and professional Institutes on Human Resource Management, Industrial Relations, Financial Management, Company Secretarial Practice, Corporate Governance and Business/Corporate laws.



## Mr. Khalilur Rahman FCS

Board Secretary

Mr. Khalilur Rahman is a Fellow Chartered Secretary (FCS) of the Institute of Chartered Secretaries of Bangladesh (ICSB). After obtaining his Master's Degree in Accounting, he completed CA Knowledge Level from the Institute of Chartered Accountants of Bangladesh (ICAB). In his 13 years career span, he took the challenge of engaging in cross-functional assignments, which refined his expertise in various areas like audit, accounts, corporate banking, tax and corporate affairs.



## Mr. Md. Abdul Haque Sarder FCS, FCA

Director (Finance & Accounts) & CFO

Mr. Abdul Haque Sarder, a Fellow Chartered Accountant of The Institute of Chartered Accountants of Bangladesh (ICAB) who has completed his Masters in Management from University of Dhaka. He is also a fellow member of the Institute of Chartered Secretaries of Bangladesh (ICSB). He has a profound and wide spread knowledge over SAP & IFRS trained by Accenture, Singapore & ICAEW, UK respectively. Prior to joining with **Beacon Pharmaceuticals Limited**, he was the CFO of Julphar Bangladesh Limited. He also served as Finance Director and Company Secretary in Syngenta Bangladesh Limited. He has more than 32 years professional experience in different managerial capacities in the country and abroad. His wide-reaching financial acumen is playing a significant role in shaping the company's present and future. He is also the member of Executive Management and Management Strategic Committee of the Company.




## Mr. Md. Jalal Uddin FCA

SVP, Head of Internal Audit

Mr. Md. Jalal Uddin is a fellow member of the Institute of Chartered Accountants of Bangladesh and Master of Business Administration. He joined in **Beacon Pharmaceuticals Limited** in April 2022 having more than 12 years of experiences in reputed corporate and professional services firm. Prior to joining Beacon Pharma, he was the head of financial governance, compliance, ethics, and integrity in Robi Axiata Limited. Mr. Jalal is highly qualified and experienced in designing policies, procedures, limits of authority, financial reporting, taxation, compliance testing, auditing, and assurance services. He is also an expert in process simplification, automation, and digitalization for large and complex operations.

# Audit Committee Nomination & Remuneration Committee Executive Management Committee



**Mr. Mohammad Ebadul Karim**  
Managing Director  
Member, Executive Management Committee



**Mr. Md. Niazul Karim**  
Director  
Member, Audit Committee,  
Nomination & Remuneration Committee (NRC)  
and Executive Management Committee



**Major M. A. Hussain (Retd.)**  
Independent Director  
Member, Audit Committee  
Chairman, Nomination & Remuneration Committee (NRC)



**Mr. Mohammad Sanaullah FCS**  
Independent Director  
Chairman, Audit Committee  
Member, Nomination & Remuneration Committee (NRC)



**Ms. Risana Karim**  
Executive Director  
Member, Executive Management Committee



**Mr. Ulfat Karim**  
Executive Director  
Member, Executive Management Committee

# Audit Committee Nomination & Remuneration Committee Executive Management Committee



**Mr. Md. Abdul Haque Sarder FCS, FCA**  
Director (Finance & Accounts) & CFO  
Member, Executive Management Committee



**Mr. Monjurul Alam**  
Director, Business Development  
Member, Executive Management Committee



**Ms. Najmun Nahar Rahman**  
Director (Plant Operations)  
Member, Executive Management Committee



**Mr. Md. Golam Robbani**  
Director, Factory Operations  
Member, Executive Management Committee



**Mr. Anisur Rahman Khan**  
EVP, HR & Admin  
Member, Executive Management Committee



**Mr. Md. Abdus Salam FCA**  
Financial Advisor  
Member, Executive Management Committee



**Mr. Khalilur Rahman FCS**  
Company Secretary (Acting)

**Mrs. Nurun Nahar Karim**  
Chairman

---



# Message from the Chairman

*The dedication of our loyal employees will strengthen the commitment to be the leading pharmaceuticals brands in Bangladesh.*

Dear shareholders,

It is my great pleasure to welcome all of you in the 21<sup>st</sup> Annual General Meeting of the Company and to place before you the Annual Report along with the Audited Financial Statements as well as Compliance Report of the Company for the year ended 30<sup>th</sup> June, 2022.

We have passed another challenging year 2021-2022. In the second half of the year the Russia-Ukraine conflict has triggered turmoil in the financial markets, and drastically increased uncertainty about the recovery of the global economy. Covid -19 is still prevailing in the world. Climate Change is one of the factors that influence deeply our Business Platform. But the Warriors of Beacon can't be lag behind. Every giant step of warriors open new era of new horizon. Our modernized technology & efficient factory management system ensure hi-tech productivity & quality of product. The dedication of our loyal employees will strengthen the commitment to be the leading pharmaceuticals brands in Bangladesh. Their strong engagement will enlighten the commitment for a stable and sustainable future

Finally, on behalf of the Board, I would like to congratulate and thank all of Beacon's employees for their hard work and perseverance throughout 2022. Another round of thanks to our all shareholders, customers, suppliers and other stakeholders for their continual support. We look forward to a successful year 2023 and we hope and believe the war between Russia-Ukraine will be end very soon.

I pray to the almighty Allah for the success of the Company in future.

*Nurun Nahar Karim*

**Nurun Nahar Karim**  
Chairman

Date: 02 November 2022

# Mr. Mohammad Ebadul Karim

Managing Director

---



# Managing Director's Overview

*Our commitment is to give the best quality service surroundings the world and give the patients smile on their face. Every patient is a liability to us. So, we do not compromise in our quality of product. Your care is our first priority.*

Dear Shareholders,  
Assalamu-Alaikum,

With hope and aspiration, I warmly welcome the valued Shareholders in our 21<sup>st</sup> Annual General Meeting. Our provision of act makes this opportunity to meet our shareholders once in a year. But Covid 19 prohibits us to make such arrangement. So, we are going to arrange 21<sup>st</sup> Annual General Meeting in digital platform for the 3<sup>rd</sup> times. It is our pleasure to present you an annual report every year.

The Russian invasion of Ukraine has happened at a time when the world just started to recover from the fallout caused by more than two years of Covid-19 pandemic. But the recovery is facing inflationary pressure due to supply shortages in the face of higher demands as countries are beginning to expand economic activities. The ongoing war has created a new shock for the world. Supply disruptions and financial sanctions pose serious economic challenges. With no signs of reconciliation between Russia and Ukraine, the global economic implications will be much more severe.

By the grace of Almighty Allah, we are pleased to report another successful year of revenue driven by a successful strategy and winning culture. Our workforces are still trying cope with the situation and take different strategies to make **Beacon Pharmaceuticals Limited** as a Brand. I believe their continuous efforts pave the way to create different market nationally and internationally.

We are pleased to report you that the sales of **Beacon Pharmaceuticals Limited** is consistently increasing in last consecutive years with higher profitability rate. During the year revenue reached Tk 8.02 billion which was higher by 12.66% over the previous year's revenue of Tk 7.12 billion. Operating profit increased by 5.01% with higher operating margins at 20.96%, as against the prior year of 19.96%. Net Profit after tax increased by 8.31 % to Tk 935 million during the year, while earnings per share increased by 8.29 %.

To consider the growing demand, we like to introduce the new product line of Cream and Ointment which will be significantly increasing our market shares in upcoming years. Apart from that, a new warehouse with larger capacity is in under construction to enhance the supply chain management and to meet our storage requirements.

## Operating Result:

- Sales Turnover has increased by 12.66% over last year.
- Gross Profit has increased by 12.48% over last year.
- Operating Profit has increased by 18.30% over last year.

- Net Profit after tax has increased by 8.31% over last year.
- Net Asset value per share has increased by 11.00% over last year.
- EPS has increased by 8.29% over last year.

### New Products

As a sophisticated pharmaceutical company, we focus our efforts where we can have the most impact. Our products are of different therapeutic segments including Norepinephrine injection, anticoagulant, pain killer, antiemetic, antibiotic, calcium supplement, hyper acidity etc.

From the very beginning, we gave extra emphasis on introducing newest molecules and advanced treatment options. That helps us reach a unique position in physician's front. Besides this, we are continuously working on our product portfolio in an attempt to providing effective and affordable treatment to the patients.

We have recently introduced Renesis 20, 50 and 100 Tablet (Roxadustat) for the management of CKD induced anemia. Pulmofib 267,534 & 801 mg tablet (Pirfenidone) is indicated for Pulmonary Fibrosis. Zaluta (Enzalutamide) 40mg tablet is a prescription medicine used to treat prostate cancer in men who have received surgery or hormone therapy to lower testosterone. Ositag (Osimertinib) 80mg tablet is used to treat non-small cell lung cancer that is positive for an abnormal "EGFR" gene. AlkriZ (Crizotinib) 250mg capsule is used to treat a type of non-small cell lung cancer (NSCLC) in people with an error in genes called ROS1 or ALK (anaplastic lymphoma kinase). Azacitid (Azacitidine) 100mg injection is used to treat Myelodysplastic syndrome (MDS), certain types of bone marrow cancers and blood cell disorders. Venclax (Venetoclax) 100mg tablet is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Ribolib (Ribociclib) 200mg tablet is used for treating hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in post-menopausal women. Nirova (Niraparib) 100mg capsule is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Miraclon (Clonazepam) for the treatment of anxiety, depression, panic attack & sleep disorder. DGM (Dextromethorphan + Guaifenesin+ Levomenthol) for the

treatment of Dry Cough, Wet Cough, Sore Throat and Nasal Congestion. Pediclor (Chloral Hydrate) for Pediatric Procedural Sedation. Fizi 5 & Fizi 10 tablet (Flunarizine) for Migraine & Vertigo. Cozid 250mg/500mg/1gm (Ceftazidime Pentahydrate): For bacterial infection management in neonates. In bacterial infection management of adult patients who are hepatic and renal impaired. Xelmet XR 500 – Preparation of Metformin extended release 500 mg tablet for management of type 2 diabetes. The extended release formulation reduces the GI disturbance and ensures patient adherence. Sinjard L 10 & 25 – Fixed dose combination preparation of Empagliflozin & Linagliptin for powerful glycemic control and superior cardio-renal protection in the management of Type 2 diabetes. Sinjard-M 500 – Combination preparation of Empagliflozin &



Metformin for Holistic management of type 2 diabetes. Glipxen-M 500 – Combination preparation of Linagliptin & Metformin for glycemic control in the management of type 2 diabetes in all stages of CKD (Chronic kidney disease) without any dose adjustment. Cardisan 25 & 100 - Preparation of Losartan Potassium. It is indicated for managing mild to moderate hypertension. Resva 5,10 & 20- Preparation of Rosuvastatin Calcium for achieving blood LDL-C goal within a short period of time. A complete Lipid profile manager.

### Our Global Business

We introduced our Global Patient Support Program in 2016 by which we are now serving our latest lifesaving drugs to the patients of more than 147 countries of the world including the developed countries of Europe, America, Australia, Africa & Asia. As lifesaving drugs are still beyond the reach of patients even in advanced countries, we introduced our products at a very affordable price and much lower than the originator's products. In this connection, the quality of our products is checked by International Standard Laboratories in USA, Australia and China, where satisfactory results have been received.

With our relentless effort we have been able to establish our Beacon as Number 1 Oncology Company of Nepal, Sri Lanka and Kenya. We have 261 registered product in 23 countries and have received GMP certificate for our plant from East-African Community, Pakistan, Philippines, Syria, Nepal, Cambodia, Sri Lanka and Kenya. Moreover, we have our own sales team in Nepal, Sri Lanka, Kenya, Uzbekistan, Pakistan, Myanmar and Uganda.

Dear shareholders, I have established this company with a global vision. Our Global Team continues adding new business spectrum in this journey. I hope that this team will make us globally more popular and Beacon becomes the trusted name to meet the scarcity of life saving drugs globally.

### Our Commitment

Our commitment is to give the best quality service surroundings the world and give the patients smile on their face. Every patient is a liability to us. So, we do not compromise in our quality of product. Your care is our first priority. Throughout the year, we have conducted various educational programs and scientific seminars in medical colleges and hospitals all over the country where thousands of practitioners and students participated. Beacon continuously facilitates doctors for acquiring updated and international standard treatment.

Moreover, Beacon has had its presence in numerous awareness programs like World Cancer Day, Colorectal Cancer Awareness Month, Breast Cancer Awareness Month, Lung Cancer Awareness Month, Cancer Survivors Program, Bangladesh International Cancer Congress etc.


We are constantly putting effort to increase our market share and introduce new products.

### Conclusion

Finally, I also express my sincere gratitude to all of our stakeholders, including Investors, Shareholders, Customers, Bankers, Medical Professionals and other participants for their whole-hearted support. We aim to passionately continue building value for our consumers and shareholders now and into the future.

I look forward to having continuous support from you all in the coming years.

With warm regards,



**Mohammad Ebadul Karim**  
Managing Director

Date: 02 November 2022

# Our people are our strength

## At Beacon, our people are our strength.

From Medical Information Officer to our functional executives and factory technicians, we work as a team. We are very proud of the work we do here. The sense of pride originates from catering to the distressed patients of cancerous diseases to minor ailments.

We ensure our employees get comfortable work sphere and function with freedom. We have exceptionally bright talents in the workforce. Multiple teams of Humans Resources and Administration Division are constantly looking after the needs of almost four thousand employees. There are competent teams to ensure everything from talent acquisition to management. We have dedicated efforts to meticulously design compensation and benefits for our hardworking employees. We acknowledge that our employees have ups and downs in life and giving them significant support to maintain their work life balance is our duty here. In this regard, we address their issues with much care.

It is in our sincere duty to constantly monitor health and safety standards at the factory and distribution depots. We also ensure that a culture of harmony and solidarity exists in all our divisional groups.

We are thoroughly introducing new facilities for the human resources in our factory, field and head office. Recently, we have established a sophisticated day care facility in head office. Our employees have brought us where are today and this is part of Beacon's commitment to serve the broader society through its employees.

Together, we are crossing milestones one after another and weaving dreams which translates to an enlightened time ahead.



# Performance Highlights



## Revenue

BDT in Million  
8,022.74



## Gross Profit

BDT in Million  
4,146.95



## Operating Profit

BDT in Million  
1,681.90



## Net Profit After Tax

BDT in Million  
935.03



## Return on Equity

15.73%



## Return on Assets

8.65%



## NAV Per Share (BDT)

25.73



## EPS Per Share (BDT)

4.05



## Market Price Per Share BDT (Closing)

258.30



## Price Earnings Share BDT (Times)

63.78

Gaviflux

# Gaviflux

Sodium Alginate USP, Sodium Bicarbonate USP & Calcium Carbonate BP

Faster Action, Faster Relief  
from **Heartburn** & **Acid Reflux**





# Ovocal-D

Calcium 500 mg (eggshell source) & Vitamin D<sub>3</sub> 200 IU Tablet


# Ovocal-DX

Calcium 600 mg (eggshell source) & Vitamin D<sub>3</sub> 400 IU Tablet

## The Premium Calcium of Bangladesh

*Quality certified by*

### TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER



## Caring Global Cancer Patients- A Decade of Innovation & Prestige for Beacon and Bangladesh

BEACON Medicare has earned a reputation as a pharmaceutical pioneer whose efforts have improved the quality of life across the globe. BEACON Medicare Limited is today the leading provider of oncological drugs and treatments in Nepal, Sri Lanka, Pakistan, Kenya & Uzbekistan and has registered 115 products in 25 different countries. To date patients from 135 countries across the globe have benefitted from BEACON's life-saving medications.

Beacon has its core in maximizing value for patients: that is, achieving the best outcomes at the lowest cost. We are moving away from a supply-driven health care system organized around what physicians do and toward a patient-centered system organized around what patients need. We are shifting the focus from the volume and profitability of services provided—physician visits, hospitalizations, procedures, and tests—to the patient outcomes achieved.


Over the years the company has regularly expanded its product range and broken new ground. It was the first pharmaceutical company in Bangladesh to manufacture drugs using lyophilisation (freeze drying); the first in the country to manufacture life-saving hepatitis products; and the first generic production company to introduce Immunotherapy (a treatment that helps the body's immune system fight cancer).

BEACON Medicare Limited inaugurated with the marketing prowess by being the only generic company globally imprudent to launch its own international conference "BEACON INTERNATIONAL CANCER SUMMIT". Nevertheless, BML is one of the Industrial Partners of European Society of Oncologists (ESMO), European Lung Cancer Congress (ELCC), Kenyan Society of Oncologists & Hematologists (KESHO), Pakistan Society of Medical Oncologists (PSMO), Pakistan Society of Hematologists (PSH), College of Oncologists-Sri Lanka and many more.





SAME **ROOT**  
SAME **FRUIT**



**Xelpac**  
Paclitaxel

**DoceXan**  
Docetaxel USP Injection

**BEACON**<sup>®</sup>  
Pharmaceuticals Limited  
*Light for life*



**IMMUNOTHERAPY**  
**THE MASTER KEY OF**  
**CANCER TREATMENT**

**NIVOMAB**  
Nivolumab Injection

**PEMRO**  
Pembrolizumab INN



## DR, ACR & NRC REPORT DECLARATION BY CEO AND CFO CORPORATE GOVERNANCE

---

# Directors' Report to the Shareholders

## For the year ended 30 June 2022

### Dear Shareholders,

The Directors have the pleasure to present their Annual Report together with the Audited Financial Statements of the Company for the year ended 30 June 2022.

This report has been prepared in compliance with section 184 of the Companies Act 1994 and Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018. In addition, the Directors explained and disclosed certain issues, which they deemed relevant and important to ensure transparency and good governance practice.

### Principal Activities

The principal activities of the Company are manufacturing, marketing and selling of pharmaceuticals and lifesaving medicine in the local and international markets.

### Property, Plant and Equipment

During the year under review, the Company invested a sum of Tk. 3,072.10 million in property, plant and equipment. Movement in property, plant and equipment during the year is disclosed under note 4 .00 of the financial statements.

### Review of Business

Despite of global economic turmoil and impact of Covid-19 pandemic, 2021-2022 was a challenging year for our company. Though situation has improved after wide vaccination initiative by the Government. However, it left a bad impact on our business. The raw materials price has significantly increased compared to previous years. As a result, product cost increased abnormally for which Gross Margin declined.

During the year revenue reached Tk 8.02 billion which was higher by 12.66% over the previous year's revenue of Tk 7.12 billion. Operating profit increased by 5.01% with higher operating margins at 20.96%, as against the prior year of 19.96%.

Net Profit after tax increased by 8.32 % to Tk 935 million during the year, while earnings per share increased by 8.29 %.

### Corporate and Financial Reporting Framework

In accordance with the Bangladesh Securities and Exchange Commission's Corporate Governance Code 2018, the Directors are pleased to confirm the following:

### Industry outlook and possible future development in the industry.

Beacon is the first manufacturer of anti-cancer drugs in Bangladesh and proud introducer of isolator technology for processing anti-cancer products and lyophilized technology. Beacon is the second in world to manufacturing and marketing peginterferon medicine for hepatitis. Beacon is the first to introduce sophisticated biotech products Streptokinase and Urokinase injections for Acute MI disease. This year Beacon has launched 20 new products, out of which 5 are general products, 8 are oncology products, 1 is bio-tech products and 6 are Chronic Care products.

Despite of the tough situation of COVID-19 we were able to maintain revenue at a reasonable level. Moreover, we have given special emphasis on cost control, resource optimization and R & D capabilities in order to face these economic challenges.

### Segment-wise or product-wise performance.

Our products can be segmented as General, Chronic Care, Oncology and Bio-tech products. In terms of volume of sale General Product is the best performer followed by Oncology and Bio-tech respectively. In terms of sales performance, general products have contributed more than 59%, 33% oncology, 6% Biotech and rest 2% contributed by Chronic Care Products. In respect of profit margin Oncology Products are the best contributor than that of others.

### Risk and Concerns.

Risks are defined as uncertainties resulting in adverse variations of profitability or losses in financials or otherwise. The risk management of the company covers core risk areas of the business operation, financial risk, operational risk, receivable risk, liquidity risk, market risk that includes foreign exchange risk, interest rate risk etc. Besides above

# Directors' Report to the Shareholders

## For the year ended 30 June 2022

risks, the Company considers credit management risks and strategic risks.

The Company has a strong base to address the risk of future uncertainties with the change of industry and global economy. The company is always keen to identify the key business risks and ensures the mitigation plans are in place. It has reviewed and adopted best practices of the industry that are articulated to enable the company to achieve its objectives effectively.

The objective of risk management is that the Company evaluates and takes well calculated business risks that safeguards the asset, its financial resources and profitability from various businesses through its own measures and by implementing corporate guidelines.

### **Cost of Goods Sold, Gross Profit Margin and Net Profit Margin.**

Cost of Goods Sold for the year stands at Tk. 3,875,791,274 which is 12.85% higher than that of the previous year. This has occurred due to increase of sales by 12.66% compare to the previous year and Gross Margin has increased by 12.48% over the last year. Besides this net margin has increased by 8.33% over the last year.

### **Extra-Ordinary gain or loss.**

No extra ordinary gain or loss occurred during the year which would require adjustment or disclosure in the financial statements.

### **Related party transactions.**

Related Party Transactions are disclosed in the notes – 48.00 to the Financial Statements for the year ended 30 June 2022.

### **Utilization of proceeds from public issues, rights issues and / or through any other instruments.**

During the financial year 2021-2022 no such proceeds are collected that would require adjustment or disclose in the annual report.

**Explanation if the financial results deteriorate after the Company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Right Offer and Direct Listing.**

**Beacon Pharmaceuticals Limited** went for initial public offering in the year 2010 and did not go for any further offering since then. So, no such explanation is required for **Beacon Pharmaceuticals Limited**.

### **Explanation of significance variance occurs between Quarterly Financial Performance and Annual Financial Statements.**

There was no significant variance that occurred between the quarterly financial performance and annual financial statements.

### **Remuneration to Directors**

This information is incorporated in the Notes 39 of the notes to the financial statements on page 124 with reference to the "Payment to Managing Director" figures concerning the Board of Directors including Independent Directors.

Remuneration and other perquisites of the Directors are reviewed annually by the NRC and approved by the Board of Directors. Non-Executive Directors Independent Directors are paid fees for attending the meetings.

### **Fairness of Financial Statements**

The financial statements together with the notes thereon have been drawn up in conformity with the Companies Act 1994 and the Securities and Exchange Rules 1987. These statements present fairly the Company's state of affairs, the result of operation, cash flow and changes in equity.

### **Proper Books of Accounts**

Books of Accounts of the Company have been maintained properly.

### **Accounting Policies**

Appropriate accounting policies have been consistently applied in preparing financial statements

# Directors' Report to the Shareholders

## For the year ended 30 June 2022

and the accounting estimates are based on reasonable and prudent judgment.

### Application of IAS and IFRS

International Accounting Standard (IAS) and International Financial Reporting Standard (IFRS) as applicable in Bangladesh have been followed in preparing financial statements and any departure has been adequately disclosed.

### Internal control

The system of internal control is sound and has been implemented and monitored effectively. The Board has the ultimate responsibility for Beacon Pharma's system of internal control and for reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material loss and that transactions are properly authorized and recorded.

### Minority Shareholders

Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.

### Going Concern.

There are no significant doubts about the Company's ability to continue as a going concern. The Board of Directors has reviewed the Company's business plan and is satisfied that the Company has adequate resources to continue its operations in the foreseeable future. Accordingly, the financial statements are prepared based on the going concern concept.

### Significant deviation from the last year's operating result.

Significant variations over the last year's operation of the Company have been made due to excess expenditure incurred in the factory overhead, general & admin overhead and selling and distribution

overhead. The positive impact of excess expenditures is gradually taking place.

### Key operating and financial data

The key operating and financial data for the last five years are annexed on page 44.

### Declaration of dividend

Based on the performance of the Company the Board of Directors is pleased to recommend a Cash Dividend @ 16% for the year 2021-2022, which is 6.67% higher than last year.

### Directors

Name of the Directors of the company and their biographical details are shown on pages 17 and 18.

### Number of board and Committee meetings

During the year, the Board of Directors met twenty-eight times. Audit Committee met four times and Nomination & Remuneration Committee met once.

The attendance record of the Directors is shown in Annexure-A of this report.

### Re-election of Director

Mr. Md. Niazul Karim retires under Article 124 of the Articles of Association of the Company, Mr. Md. Niazul Karim eligible and offered himself for re-election. The Board recommends his re-appointment.

### Appointment of Independent Director

Mr. Abdul Qader Siddiqui Independent Director of the Company submitted his resignation as Independent Director which was accepted by the Board on 1<sup>st</sup> June 2022. Members of the Board gratefully acknowledged the valuable contributions of Mr. Abdul Qader Siddiqui during his tenure of office.

Based on the recommendation of the Nomination and Remuneration Committee and approval of

# Directors' Report to the Shareholders

## For the year ended 30 June 2022

Bangladesh Securities and Exchange Commission (BSEC), the Board of Directors of the Company appointed Mr. Mohammad Sanaullah FCS as Independent Director of the Company for three years (First term) with effect from June 29, 2022. Mr. Sanaullah has long experienced in corporate management and hold the position as Director in different listed Companies including MNC.

### Board Committees

In accordance with the condition no.6 of Bangladesh Securities and Exchange Commission's Code of Corporate Governance, BSEC/CMRRCD/2006/158/ 207/Admin/80, dated 3rd June, 2018, the Board of Beacon Pharmaceutical Limited have reformed the following Committee's in its meeting held on June 29, 2022:

#### Audit Committee

SI No.	Name	Position
1	Mr. Mohammad Sanaullah, Independent Director	Chairman
2	Major M.A Hussain (Retd.), Independent Director	Member
3	Mr. Md. Niazul Karim, Director	Member

#### Nomination and Remuneration Committee

SI No.	Name	Position
1	Major M.A Hussain (Retd.), Independent Director	Chairman
2	Mr. Mohammad Sanaullah, Independent Director	Member
3	Mr. Md. Niazul Karim, Director	Member

#### Appointment of Statutory Auditors

As per section 210 of the Companies Act 1994, the Company's statutory Auditors Messrs. Toha Khan Zaman & Co, Chartered Accountants retires at the 21st Annual General Meeting as Statutory Auditors of the Company.

As per the Bangladesh Securities and Exchange Commission (BSEC) order no SEC/CMRRCD/2009-193/104/Admin dated July 27, 2011 the retiring Auditors M/S Toha Khan Zaman & Co , Chartered Accountants are eligible for re-appointment as Statutory Auditors for 2022-2023.

The Audit Committee recommended to appoint Messer's Toha Khan Zaman & Co, Chartered Accountants as the auditors of the Company for the year 2022-2023 at a fee of Tk. 375,000 (Taka three lakh seventy -five thousand) only.

The Directors have endorsed the recommendation of the Audit Committee for re-appointment of Messer's Toha Khan Zaman & Co, Chartered Accountants as the Statutory Auditors for the year 2022-2023.

#### Appointment of Corporate Governance Compliance Auditors

The Audit Committee recommended to appoint M/S Al- Muqtadir Associates, Chartered Secretaries and Consultants as the Corporate Governance Compliance Auditors of the company for the year 2022-2023.

The Board of Directors have endorsed the recommendation of the Audit Committee for appointment of M/S Al- Muqtadir Associates., Chartered Secretaries & consultants as the Corporate Governance compliance Auditor auditors of the company for the year 2022-2023 at a fee of Tk.80,000 (Taka eighty thousand) only.

# Directors' Report to the Shareholders

For the year ended 30 June 2022

## Pattern of Shareholding:

a) Parent/Subsidiary/ Associated Companies and other related parties.

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of Share held
01	Mr. Mohammad Ebadul Karim	Managing Director	Beacon Developments Limited	600
			MEK Auto Bricks	25,000
			MEK Industries Limited	8,500
			MEK Pharmatech Limited	8,500
			Mujibunnessa Medical College & Hospital Limited	80,00,000
			Beacon Oncology Limited	85,000
			Beacon Nutraceuticals Limited	85,000
		Chairman	Beacon Cephalosporin Limited	25,50,000
			Beacon Power Systems Limited	85,000
			Beacon Point Limited	25,000
			Beacon Medicare Limited	42,500
			EREBA Capsules Limited	20,000
			Beacon Economic Zone Limited	8,00,000
			Beacon Business Solution Limited	85,000
		Director	Kohinoor Chemical Co. (BD) Limited	1,998,275

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of Share held
02	Mrs. Nurun Nahar Karim	Chairman	Beacon Developments Limited	250
			Beacon Nutraceuticals Limited	5,000
			MEK Auto Bricks	12,500
			MEK Industries Limited	500
			MEK Pharmatech Limited	500
			Beacon Oncology Limited	5,000
			Mujibunnessa Medical College & Hospital Limited	5,00,000
		Director	Beacon Cephalosporin Limited	1,50,000
			Beacon Power Systems Limited	5,000
			Beacon Point Limited	25,000
			Beacon Medicare Limited	2,500
			Beacon Economic Zone Limited	50,000
			Beacon Business Solution Limited	5,000
			Kohinoor Chemical Co. (BD) Limited	1,277,579
			Banani Clinic Limited	10,000

# Directors' Report to the Shareholders

For the year ended 30 June 2022

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of Share held
03	Mr. Md. Niazul Karim	Managing Director	Beacon Point Limited	25,000
			Beacon Economic Zone Limited	1,50,000
			Beacon Medicare Limited	2,500
		Director	Beacon Developments Limited	400
			Beacon Cephalosporin Limited	1,50,000
			Beacon Nutraceuticals Limited	5,000
			MEK Auto Bricks	6,250
			MEK Industries Limited	500
			MEK Pharmatech Limited	500
			Beacon Oncology Limited	5,000
			Mujibunnessa Medical College & Hospital Limited	5,00,000
			Beacon Business Solution Limited	5,000
			Beacon Power Systems Limited	5,000

b) Director, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and their spouse and minor children.

Sl. No.	Name	Designation	No. of Shares Held
1	Mr. Mohammad Ebadul Karim	Managing Director	5,82,28,800
2	Mrs. Nurun Nahar Karim	Director	47,25,000
3	Mr. Md. Niazul Karim	Director & CFO	63,54,000
4	Mr. Md. Abdul Haque Sarder	Director, (F & A) and CFO	Nil
5	Mr. Khalilur Rahman FCS	Company Secretary	Nil
6	Mr. Md. Jalal Uddin FCA	Head of Internal Audit	Nil
7	Spouse & Minor Children		Nil

c) Executive

Sl. No.	Name	Designation	No. of Shares Held
1	Mr. Mohammad Ebadul Karim	Managing Director	5,82,28,800
2	Mr. Monjurul Alam	Director, Business Development	64,500
3	Ms. Najmun Nahar Rahman	Director (Plant Operations)	Nil
4	Mr. Md. Golam Robbani	Director, Factory Operations	Nil
5	Mr. Anisur Rahman Khan	EVP, HR & Admin	Nil

d) Shareholders holding ten percent (10%) or more voting interest in the Company.

Sl. No.	Name	Designation	No. of Shares Held
1	Mr. Mohammad Ebadul Karim	Managing Director	5,82,28,800

# Directors' Report to the Shareholders

For the year ended 30 June 2022

## Corporate Governance Compliance Report:

**Beacon Pharmaceuticals Limited** adheres to appropriate good Corporate Governance principles. The Company also complied with all the requirements of Corporate Governance as required by the Bangladesh Securities and Exchange Commission. Accordingly, Corporate Governance Compliance checklist is shown in Annexure-1 of this report.

Further in compliance with the requirement of the Bangladesh Securities and Exchange Commission's (BSEC) Corporate Governance Code 2018, M/S Podder & Associates, Cost & Management Accountants in Practice issued the Corporate Governance Compliance Certificate which is shown on page no. 75 of the report.

## Contribution to the National Exchequer

During the year under review, our company paid Taka 1,678.05 million to the national exchequer in the form of corporate income tax, customs duties and value added tax.

## Credit Rating

The Company achieved A1 rating in long term and ST-3 for short term for consecutive three years with a strong and stable outlook from Credit Rating Agency of Bangladesh Limited (CRAB).

## Reserves

The total Reserves of the Company stood at Tk. 1231.06 million, details of which are given in Note 15 and in the Statement of Changes in Equity in the Financial Statements.

## Events subsequent to Balance Sheet

The Board of Directors in their meeting held on October 25, 2022 recommended cash dividend @ 16% for the year 2021-22.

## CEO and CFO's Declaration to Financial Statements

The Chief Executive Officer and Chief Financial Officer are of the opinion that Financial Statements given true and fair view of the company's affairs.

## Human Resources

A dynamic business environment requires having a well-trained work force; therefore, the company develops the appropriate management skills to suit the business environment. Various training programs and workshops were carried out during the year. The management and employee relationship in the company was excellent throughout the year.

## Compliance with Laws and Regulations

The company was not engaged in any activities contravening the laws and regulations. All those responsible for ensuring compliance with the provisions in various laws and regulations were able to do so within the stipulated time.

## Environmental Protection

To the best of the Board's knowledge, the company was not engaged in any activity which might prove harmful to environment.

## Conclusion:

The Company expresses its sincere appreciation to all of its employees for their outstanding contribution and thanks to all the stakeholders for their continued support and confidence.

On behalf of the Board of Directors

*Nurun Nahar Karim*  
Mrs. Nurun Nahar Karim  
Chairman  
Date : 24 October 2022

# Directors' Report to the Shareholders

For the year ended 30 June 2022

## 5 YEARS FINANCIAL HIGHLIGHTS

Taka in 000

Particulars	Particulars				
	2022	2021	2020	2019	2018
<b>Financial Performance</b>					
Total Assets	10,815,897,392	8,535,571,691	7,176,904,014	4,871,002,971	4,908,410,740
Total Liabilities	4,87,20,46,906	3,180,408,738	2,546,558,381	1,891,819,980	1,907,666,832
Current Assets	6,444,215,802	5,215,795,475	3,785,627,854	2,668,641,600	2,400,038,430
Current Liabilities	4,674,132,541	2,792,662,114	2,053,537,586	1,317,400,721	1,332,666,250
Non-Current Assets	4,371,681,590	3,319,776,214	3,391,276,160	2,202,361,371	2,508,372,310
Non-Current Liabilities	197,914,365	387,746,624	493,020,794	574,419,259	575,000,582
Shareholders' Equity	5,943,850,486	5,355,162,953	4,630,345,633	2,979,182,991	3,000,743,908
<b>Operational Performance</b>					
Revenue	8,022,736,306	7,121,152,785	5,590,790,317	4,646,865,410	3,760,786,106
Cost of Goods Sold	3,875,791,274	3,434,422,533	2,718,444,324	2,364,808,809	1,927,331,673
Operating Expense	2,465,035,491	2,265,106,526	2,529,653,717	1,959,448,364	1,563,846,092
Financial Expense	339,380,959	166,796,221	150,270,407	153,524,466	138,160,282
Gross Profit	4,146,945,032	3,686,730,252	2,872,345,993	2,282,056,601	1,833,454,433
Operating Profit	1,681,909,541	1,421,623,726	342,692,277	322,704,069	269,608,341
Net Profit before tax	1,292,967,761	1,198,163,031	184,503,417	163,400,976	126,035,753
Net Profit after tax	935,187,533	863,417,319	380,691,353	117,700,592	126,103,008
<b>Financial Ratio</b>					
Current ratio	1.38:1	1.87:1	1.84:1	2.03:1	1.80:1
Debt Equity Ratio	0.82:1	0.59:1	0.55:1	0.64:1	0.64:1
Financial Expense Coverage Ratio (Times)	4.96	8.52	2.28	2.1	1.95
Return on Equity	15.73%	16.12%	8.22%	3.95%	4.20%
Return on Assets	8.65%	10.11%	5.30%	2.42%	2.57%
<b>Equity Parameters</b>					
Authorized Capital	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000
Paid-up Capital	2,310,000,000	2,310,000,000	2,310,000,000	2,310,000,000	2,310,000,000
Shareholders' Equity	5,943,850,486	5,355,162,953	4,630,345,633	2,979,182,991	3,000,743,908
No. of Shares Outstanding	231,000,000	231,000,000	231,000,000	231,000,000	231,000,000
Net Assets Value (NAV) Per Share	25.73	23.18	20.04	12.9	12.99
Earnings Per Share (EPS)	4.05	3.74	1.65	0.51	0.55
Market Price Per Share (Closing)	258.30	123.60	60.7	20.1	17.8
Price Earnings Ratio (Times)	63.78	33.05	36.79	39.41	32.36

# Directors' Report to the Shareholders

For the year ended 30 June 2022

ANNEXURE- A

## Board /Committee Meetings and attendance during the year ended June 30, 2022

### (a) Board Meeting

Sl. No.	Name of Directors	Meeting held	No. of meeting attended
1	Ms. Nurun Nahar Karim, Chairman	28	28
2	Mr. Mohammad Ebadul Karim, Managing Director	28	28
3	Mr. Md. Niazul Karim, Director	28	28
5	Major M. A. Hussain (Retd.), Independent Director	28	6
6	Mr. Abdul Qader Siddiqui, Independent Director	28	5

### (b) Audit Committee Meeting

Sl. No.	Name of Directors	Position	Meeting held	No. of meeting attended
1	Mr. Abdul Qader Siddiqui	Chairman	4	3
2	Major M. A. Hussain (Retd.)	Member	4	4
3	Mr. Md. Niazul Karim	Member	4	4

### (c ) Nomination & Remuneration Committee Meeting

Sl. No.	Name of Directors	Position	Meeting held	No. of meeting attended
1	Major M. A. Hussain (Retd.)	Chairman	1	1
2	Mr. Abdul Qader Siddiqui	Member	1	
3	Mr. Md. Niazul Karim	Member	1	1

# Audit Committee Report

## Composition of the Audit Committee

The Audit Committee is a sub-committee of the Board. The Board has reformed the Audit Committee on 29 June 2022, as stated below. The Committee comprises three Directors including two independent directors. The Chairman of the Committee is an Independent Director. The Chief Financial Officer (CFO) and Head of Internal Audit (HIA) attend the meetings by invitation. The Company Secretary functions as the Secretary of the Committee.

SI No.	Name	Position
1	Mr. Mohammad Sanaullah FCS	Chairman
2	Mr. Md. Niazul Karim	Member
3	Major M.A Hussain (Retd.)	Member
4	Mr. Khalilur Rahman FCS	Secretary

## Role and responsibilities of the Committee

The Audit Committee is empowered to consider any matter relating to the financial affairs of the Company and to review all internal and external audits, internal control systems and procedures, accounting policies, etc., so as to ensure that a sound financial reporting system is in place and is well managed, in order to provide accurate, appropriate and timely information to the Management, Regulatory Authorities and to the Shareholders.

## Meetings and Attendance

During the financial year ended on 30 June 2022, four meetings of the Audit Committee were held. The details of attendance of the members have been shown in the ANNEXTURE-A of page 45 of the annual report.

The Company's external auditors representative was present at the pre-AGM Audit Committee meeting where matters relating to the audit of the statutory accounts were discussed.

## Summary of Activities

The following activities were carried out by the Audit Committee during the financial year ended on 30 June 2022.

## Financial Reporting

- Reviewed the quarterly, half yearly and interim financial statements of the Company and the relevant announcements to the Stock Exchanges by the Board of Directors;
- Reviewed the annual financial statements of the Company prior to submission to the Board of Directors. The review was to ensure that the financial reporting and disclosures were in compliance with the Securities Laws, provisions of the Companies Act 1994, International Financial Reporting Standards (IFRS) as applicable in Bangladesh, any conflict of interest and other relevant legal and regulatory requirements.

# Audit Committee Report

## Internal Audit

- Reviewed the Internal Audit reports which encompassed the audit issues, audit recommendations and Management's responses to these recommendations. Improvement actions in the areas of internal controls, systems and efficiency enhancements suggested by the internal auditors were discussed together with Management.
- Reviewed the implementation of these recommendations through follow-up audit reports to ensure all key areas were addressed.
- Suggested additional improvement opportunities in the areas of internal control, systems and efficiency improvement.


## External Audit

- The Committee met with external auditors at the conclusion of the annual audit and discussed on the presentation of financial statements.
- Reviewed with the external auditors about their audit scopes, audit strategies and audit plans for the year and their proposed fees for the statutory audit and reviewed of the Statement of Internal Control.
- Reviewed the performance of the external auditors and made recommendation to the Board on their appointment and fees.

## Recommendation

- The Audit Committee recommended to the Board of Directors that M/s. Toha Khan Zaman & Co; Chartered Accountants be re-appointed as Statutory Auditors for the financial year ending on June 30, 2023 at a fee of Tk. 375,000 (Taka Three Lakhs seventy-five thousand) only subject to the approval of the members at the 21st Annual General Meeting of the Company.
- The Committee also recommended to the Board that M/s. Al Muqtadir Associates Chartered Secretaries and Consultants be appointed as Corporate Governance Compliance Auditors for the financial year ending on June 30, 2023 at a fee of Tk. 80,000 (Taka Eighty thousand) only subject to the approval of the members at the 21st Annual General Meeting of the Company.

On behalf of the Audit Committee



**Mohammad Sanaullah**  
Chairman  
Audit Committee

Date: 24 October 2022

# Nomination and Remuneration Committee Report

## Composition of Nomination and Remuneration Committee:

The Nomination and Remuneration Committee (NRC) is the sub-committee of the Board. The Board of Directors of the Company has duly reformed the Nomination and Remuneration Committee (NRC) on 29 June 2022 comprising the three Directors including two Independent Directors. The Chairman of Committee is an Independent Director. The Chief Financial Officer (CFO) and Head of Internal Audit (HIA) attend the meetings by invitation. The Company Secretary functions as the Secretary of the Committee.

SI No.	Name	Position
1	Major M.A Hussain (Retd.)	Chairman
2	Mr. Md. Niazul Karim, Director	Member
3	Mr. Mohammad Sanaullah FCS	Member
4	Mr. Khalilur Rahman FCS	Secretary

## Meetings held of the NRC:

In the year 2021-22, one meeting was held of the Nomination and Remuneration Committee during the year where a detailed discussion was made relating to the nomination and remuneration policy and the evaluation criteria and activities of NRC. The details of attendance of the members have been shown in the ANNEXTURE-A of page 45 of the annual report.

## Role and Responsibility of the Nomination and Remuneration Committee:

Major Role and Responsibilities of the Nomination and Remuneration Committee are as follows:

- Formulate the criteria for determining qualification, positive attributes of Directors;
- Recommend a policy to the Board relating to the remuneration of the Directors, and top level executives;
- Formulate the criteria for evaluation of performance of Independent Directors and the Board;
- Devising a policy on Board's diversity taking into consideration age, gender, experience, education and nationality;
- Identify persons who are qualified to become Directors and in top level executives and recommend their appointment and removal;
- Assess that the level and composition of remunerations reasonable and sufficient to attract, retain and motivate suitable Directors to run the company successfully;
- Recommend and review annually the Company's human resources and training policies;
- Evaluate that remuneration to Directors and top level executives involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- Recommend the Code of Conduct for the Chair of the Board, other Board Members and Chief Executive Officer of the Company.

# Nomination and Remuneration Committee Report

## Activities of the NRC during reporting period

- Proposed the name of the Board of Directors for retirement by rotation and re-election (being eligible) complying with the related Laws, Rules and Regulations.
- Proposed the names of Independent Director to comply with corporate governance code imposed by BSEC.
- Performance evaluation of the Board, individual members of the Board and the top level executives of the company.
- To Prepare a NRC report for publishing in the Annual Report 2021-22 of the company.

Nomination and Remuneration Committee (NRC) expresses their sincere thanks to the Board of Directors and Management for their support, guidance and co-operation.

On behalf of the Audit Committee



Major M.A Hussain (Retd.)  
Chairman  
NRC

Date: 24 October 2022

# Declaration by CEO and CFO

Date: 23 October 2022  
The Board of Directors  
**Beacon Pharmaceuticals Limited**  
Beacon Business Center  
9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223.

**Subject: Declaration on Financial Statements for the year ended on 30 June 2022.**

Dear Sirs,


Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006 158/207/Admin/ 80, Dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance 1969, we do hereby declare that:

- 1) The Financial Statements of **Beacon Pharmaceuticals Limited** for the year ended on 30 June, 2022 have been prepared in compliance with International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
- 2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- 3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- 4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- 5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- 6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriated and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.


**In this regard, we also certify that:-**

- i) We have reviewed the financial statements for the year ended on 30 June 2022 and that to the best of our knowledge and belief-
  - a) these statements do not contain any materiality untrue statement or omit any material fact or contain statements that might be misleading;
  - b) these statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



**Mohammad Ebadul Karim**  
Managing Director








**Md. Abdul Haque Sarder FCS, FCA**  
Director (F & A) and CFO

# Paloxi

Palonosetron USP

**Power over EMESIS**



-  **Cardiac Safe Antiemetic**
-  **Does not cause any abnormality in heart rhythm**
-  **Once daily dosing ensures maximum patients compliance**
-  **No dose adjustment is needed for hepatic and renal impaired patients**
-  **Only effective antiemetic for both acute & delayed nausea-vomiting**

# Montinex

Montelukast Sodium BP 4 mg, 5 mg & 10 mg Tablet

**The First CEP Certified Montelukast in Bangladesh**

API from  **Mylan**<sup>®</sup>

- ❖ Enantiomeric Purity 100%.
- ❖ Safe for long term use in the management of Asthma, COPD & Allergic Rhinitis.



# A Guideline of Transparency and Accountability

## Corporate Governance

Adopting the best practice of Corporate Governance and following the principles of transparency and accountability that protect the interest of its stakeholders and safeguarding the assets of the shareholders. Corporate Governance ensures the activities that lead the Company to its goal through setting strategies, formulating policies and taking prudent decisions. The Board of Directors of Beacon ensures that the activities undertaken by the Company are in accordance with the highest ethical standards in the best interest of all stakeholders.

## The Board

The Board comprises five members of executive and non-executive having diverse and professional skill and experience. The non-executive Directors are from different business and background. Their experience enables them contribute the Company in making strategy, formulating policy and other decision making process for advancement. The Chairman is the head of the Board and Company Secretary is the compliance officer who prepares agenda in consultation with the Chairman of the Board of Directors and Chairman of various Committee and Managing Director. The Chairman ensures that all Board members are properly briefed on all issues raise in the Board Meeting. It is the responsibility of the Chairman and the Company Secretary to ensure that the non-executive Directors are provided with timely information to enable them to carry on the duties effectively.

## Board Meetings

The Board of Directors has the supreme authority delegated by the shareholders in making strategy, formulating policy and other decision making process for development of the Company. The Board of Directors considers that it meets regularly to discharge their duties effectively.

## Board Independence

As per Corporate Governance Guidelines, Major M. A. Hussain (Retd.) and Mr. Mohammad Sanaullah FCS have been appointed as Independent Director of the

Company. They are considered by the Board to be independent of the Company and the management and free of any business or other relationship that could interfere with the exercise of their independent judgment. The Board believes that, their experience and knowledge enable them to provide effective and constructive contribution to the Board.

## Board Committee

The Board of Directors has formed a number of committees to assist in exercising its authority including monitoring of performance.

## Audit Committee

The Company's Audit Committee met fourth times in the year 2021-22 to consider its Annual Financial Statements for the year ended 30th June, 2022 and the Quarterly Reports in the same financial year. The committee comprises Mr. Mohammad Sanaullah FCS, Mr. Md. Niazul Karim and Major M.A Hussain (Retd.).

## Nomination and Remuneration Committee

The Company's Nomination and Remuneration Committee met one time in the year 2021-22 to developing, recommending and reviewing annually the company's human resources and training policies. The committee comprises Major M.A Hussain (Retd.), Mr. Md. Niazul Karim and Mr. Mohammad Sanaullah FCS.

## Internal Control

The Board has ultimate responsibility of Beacon Pharma's system of internal control and reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material losses and that transactions are properly authorized and recorded.

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

ANNEXURE-C  
As Per condition no.1(5)(xxvii)

Status of compliance with the conditions imposed by the Commission's Notification No.BSEC/CMRRCD/2006-158/207/Admin/80, dated 03 June, 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9.00)

Condition No.	Title	Complied	Not Complied	Remarks (if any)
<b>1</b>	<b>Board of Directors.-</b>			
<b>1(1)</b>	<b>Size of the Board of Directors</b>			
	The total number of members of a company's Board of Directors (hereinafter referred to as "Board") shall not to be less than 5 (five) and more than 20 (twenty).	√	-	The Board of Directors is comprised of 05 (Five) Directors including 02 (Two) Independent Directors.
<b>1(2)</b>	<b>Independent Directors</b>			
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s);	√	-	There are (02) Two Independent Directors in the BPL Board.
1(2)(b)	For the purpose of this clause "independent director" means a director-			
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	√	-	
1(2)(b)(ii)	Who is not a sponsor of the company and is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(2)(b)(iii)	Who has not been an executive of the company in immediately preceding 2( two) financial years;	√	-	
1(2)(b)(iv)	Who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	√	-	
1(2)(b)(v)	Who is not a member or TREC ( Trading Right Entitlement Certificate) holder, director, or officer of any stock exchange;	√	-	
1(2)(b)(vi)	Who is not a shareholder, director excepting independent direct or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	√	-	
1(2)(b)(vii)	Who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	√	-	
1(2)(b)(viii)	Who is not an independent director in more than 5 (five) listed companies;	√	-	
1(2)(b)(ix)	Who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI);	√	-	
1(2)(b)(x)	Who has not been convicted for a criminal offence involving moral turpitude.	√	-	
1(2)(c)	The independent director(s) shall be appointed by the board of directors and approved by the shareholders in the Annual General Meeting (AGM).	√	-	After last AGM one new independent director has been appointed by the board and waiting for approval in the next AGM
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90(ninety) days.	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(2)(e)	The tenure of office of an independent director shall be for a period of 3(three) years, which may be extended for 1(one) term only.	√	-	
1(3)	<b>Qualification of Independent Director.-</b>			
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to business;	√	-	
1(3)(b)	<b>Independent Director shall have following qualifications:</b>			
1(3)(b)(i)	Business Leader who is or was a promoter or director of an unlisted company having minimum paid -up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association; or	-	-	N/A
1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company; or	√	-	
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or law; or	√	-	
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law; or	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	√	-	
1(3)(c)	The independent director(s) shall have at least 10( ten) years of experiences in any field mentioned in clause (b);	√	-	N/A
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission.	-	-	No such deviation occurred
1(4)	<b>Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer.-</b>			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	√	-	
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	√	-	
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	√	-	
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/ or Chief Executive officer;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√	–	No such event arose during the year
<b>1(5)</b>	<b>The Directors' Report to the Shareholders</b>			
1(5)(i)	An industry outlook and possible future developments in the industry;	√	–	
1(5)(ii)	The Segment-wise or product-wise performance;	√	–	
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√	–	
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√	–	
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	√	–	No such issue arose
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√	–	
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or through any others instruments;	–	–	N/A
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc.;	–	–	N/A
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial Performance and Annual Financial Statements;	√	–	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	√	-	
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√	-	
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	√	-	
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√	-	
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	√	-	
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	√	-	
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√	-	
1(5)(xvii)	A statement that there is no significant doubt upon the issuer company's ability to continue as going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	√	-	
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	√	–	
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;	–	–	The Board of Directors has recommended 16% cash dividend for the year ended on June 30, 2022.
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	–	–	N/A
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	√	–	
1(5)(xxiii)	<b>A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:-</b>			
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	–	–	N/A
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance their spouses and minor children (name- wise details);	√	–	
1(5)(xxiii)(c)	Executives; and	√	–	
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details).	√	–	
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:-			
1(5)(xxiv)(a)	a brief resume of the director	√	–	
1(5)(xxiv) (b)	nature of his/her expertise in specific functional areas;	√	–	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(xxiv) (c)	names of companies in which the person also holds the directorship and the membership of committees of the Board;	√	-	
1(5)(xxv)	<b>Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in financial statements, among others, focusing on:</b>			
1(5)(xxv)(a)	accounting policies and estimation for preparation of financial statements;	√	-	
1(5)(xxv)(b)	changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	√	-	
1(5)(xxv)(c)	comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√	-	
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√	-	
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	√	-	
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	√	-	
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√	-	
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A; and	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	√	-	
<b>1(6)</b>	<b>Meetings of the Board of Directors</b>			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	√	-	
<b>1(7)</b>	<b>Code of Conduct for the Chairperson, other Board members and Chief Executive Officer</b>			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC), at condition No.6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	√	-	
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	√	-	
<b>2</b>	<b>Governance of Board of Directors of Subsidiary Company:-</b>	<b>BPL doesn't have any subsidiary Company</b>		
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	-	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
2(b)	At least 1 (one) independent director of the Board of the holding company shall be a director on the Board of the subsidiary company;	-	-	
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	-	-	
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	-	-	
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	-	-	
3.	<b>Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO) Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS):-</b>			
3(1)	<b>Appointment</b>			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√	-	
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√	-	
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	√	-	
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	√	-	
3(2)	<b>Requirement to attend Board of Director's Meetings</b>			
	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board: Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	√	-	
3(3)	<b>Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer(CFO)</b>			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	√	-	
3(3)(a)(i)	these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√	-	
3(3)(a)(ii)	these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√	-	
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its member;	√	-	
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	√	-	Disclosed in the Annual Report

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
4.	<b>Board of Director's Committee.- For ensuring good governance in the company, the Board shall have at least following sub-committees:</b>			
4(i)	Audit Committee; and	√	-	
4(ii)	Nomination and Remuneration Committee	√	-	
5.	<b>Audit Committee.-</b>			
5(1)	<b>Responsibility to the Board of Directors.</b>			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	√	-	
5(1)(b)	The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	√	-	
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	√	-	
5(2)	<b>Constitution of the Audit Committee</b>			
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	√	-	
5(2)(b)	The Board shall appoint members of the audit committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1(one) independent director;	√	-	
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(2)(d)	When the term of service of any Committee members expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√	-	
5(2)(e)	The company secretary shall act as the secretary of the Committee.	√	-	
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	√	-	
<b>5(3)</b>	<b>Chairperson of the Audit Committee</b>			
5(3)(a)	The Board of Directors shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an Independent director;	√	-	
5(3)(b)	In the absence of the Chairperson of the audit committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No.5(4)(b) and the reason of absence of the regular chairperson shall be duly recorded in the minutes.	√	-	
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM): Provided that in absence of Chairperson of the Audit Committee, any other member from the Audit Committee shall be selected to be present in the annual general meeting (AGM) and reason for absence of the Chairperson of the Audit Committee shall be recorded in the minutes of the AGM.	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(4)	<b>Meeting of the Audit Committee</b>			
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year: Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	√	-	
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√	-	
5(5)	<b>Role of Audit Committee :-</b>			
	The Audit Committee shall:-			
5(5)(a)	Oversee the financial reporting process;	√	-	
5(5)(b)	monitor choice of accounting policies and principles;	√	-	
5(5)(c)	monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√	-	
5(5)(d)	oversee hiring and performance of external auditors.	√	-	
5(5)(e)	hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	√	-	
5(5)(f)	review along with the management, the annual financial statements before submission to the board for approval;	√	-	
5.5(g)	review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5.5(h)	review the adequacy of internal audit function;	√	–	
5(5)(i)	review the Management's Discussion and Analysis before disclosing in the Annual Report;	√	–	
5(5)(j)	review statement of all related party transactions submitted by the management;	√	–	
5(5)(k)	review Management Letters or Letter of Internal Control weakness issued by statutory auditors.	√	–	
5(5)(l)	oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and	√	–	
5(5)(m)	oversee whether the proceeds raised through Initial public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purpose stated in relevant offer document or prospectus approved by the Commission:	√	–	
5(5)(m)	oversee whether the proceeds raised through Initial public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purpose stated in relevant offer document or prospectus approved by the Commission:	√	–	
<b>5(6)</b>	<b>Reporting of the Audit Committee</b>			
<b>5(6)(a)</b>	<b>Reporting to the Board of Directors</b>			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	√	–	
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board on the following findings, if any:-	√	–	
5(6)(a)(ii)(a)	report on conflicts of interests;	–	–	No such reportable incidence arose

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;	-	-	No such reportable incidence arose
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;	-	-	No such reportable incidence arose
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;	-	-	No such reportable incidence arose
5(6)(b)	<b>Reporting to the Authorities:-</b>			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.	-	-	No such reportable incidence arose
5(7)	<b>Reporting to the Shareholders and General Investors</b>			
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	-	-	No such reportable incidence arose
6.	<b>Nomination and remuneration Committee(NRC).-</b>			
6(1)	<b>Responsibility to the Board of Directors</b>			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√	-	
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	√	-	
<b>6(2)</b>	<b>Constitution of the NRC</b>			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	√	-	
6(2)(b)	All member of the Committee shall be non-executive directors;	√	-	All the NRC members are non-executive Directors including Independent Directors
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	√	-	
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	√	-	
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	-	-	No such Incidence arose
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	-	-	No such occurrence happen during the year

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(2)(g)	The company secretary shall act as the secretary of the Committee;	√	-	
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	√	-	
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	√	-	
<b>6(3)</b>	<b>Chairperson of the NRC</b>			
6(3)(a)	The Board shall select 1(one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√	-	
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	√	-	
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders;	√	-	
<b>6(4)</b>	<b>Meeting of the NRC</b>			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√	-	
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	-	-	No such case arose after formation of NRC
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√	-	
<b>6(5)</b>	<b>Role of the NRC</b>			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	√	-	
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board:	√	-	
6(5)(b)(i)	formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:	√	-	
6(5)(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√	-	
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	√	-	
6(5)(b)(i)(c)	remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	√	-	
6(5)(b)(ii)	devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√	-	
6(5)(b)(iii)	identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
6(5)(b)(iv)	formulating the criteria for evaluation of performance of independent directors and the Board;	√	-	
6(5)(b)(v)	identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	√	-	
6(5)(b)(vi)	developing, recommending and reviewing annually the company's human resources and training policies;	√	-	
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	√	-	
<b>7.</b>	<b>External or Statutory Auditors</b>			
7(1)	The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely :-			
7(1) (i)	appraisal or valuation services or fairness opinions;	√	-	
7 (1) (ii)	financial information system design and implementation;	√	-	
7 (1) (iii)	book-keeping or other services related to the accounting records or financial statements;	√	-	
7 (1) (iv)	broker –dealer services;	√	-	
7 (1) (v)	actuarial services;	√	-	
7 (1) (vi)	internal audit services or special audit services;	√	-	
7 (1) (vii)	any services that the Audit Committee determines.	√	-	
7 (1) (viii)	Audit or certification services on compliance of corporate governance as required under condition No.9(1);	√	-	
7 (1) (ix)	any other service that creates conflict of interest	√	-	

# Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30 June 2022

Condition No.	Title	Complied	Not Complied	Remarks (if any)
7(2)	No Partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company:	√	-	
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' meeting (Annual General meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	√	-	
<b>8.</b>	<b>Maintaining a website by the Company.-</b>			
8(1)	The Company shall have an official website linked with the website of the stock exchange.	√	-	
8(2)	The company shall keep the website functional from the date of listing.	√	-	
8(3)	The company shall make available the detailed disclosures on its website as required under the regulations of the concerned stock exchange(s)	√	-	
<b>9.</b>	<b>Reporting and Compliance of Corporate Governance.-</b>			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	√	-	Required certification has been obtained from "PODDER & ASSOCIATES" Cost & Management Accountants for the year ended 30th June 2022.
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the Shareholders in the annual general meeting.	√	-	
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	√	-	



## PODDER & ASSOCIATES

Cost and Management Accountants

### Annexure-B

[Certificate as per condition No. 1(5)(xxvii)]

#### **Report to the Shareholders of Beacon Pharmaceuticals limited on compliance on the Corporate Governance Code.**

We have examined the compliance status to the Corporate Governance Code by **Beacon Pharmaceuticals Limited** for the year ended on June 30, 2022. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission;
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws ; and
- (d) The governance of the company is satisfactory.

**For Podder & Associates**

Jayanta Kumer Podder  
Cost & Management Accountants

Place: Dhaka  
Dated: November 17, 2022

# DIRECTORS' RESPONSIBILITIES



# Directors' Responsibilities for the Financial Statements

The Directors are responsible for preparing the annual report and financial statements in accordance with the Company's Act.1994, Bangladesh Securities and Exchange Commission Rules 1987, International Financial Reporting Standards (IFRS) and other applicable laws and regulations.

The Company's Act. 1994 requires Directors to ensure that the Company keeps proper books of accounts of all transactions and prepares financial statements that give a true and fair view of the state of the Company's affairs and of the profit for the year.

The Directors are also required to ensure that the financial statements have been prepared and presented in accordance with the International Financial Reporting Standards (IFRS) as applicable in Bangladesh and provided the information required by the Company's Act 1994, Securities and Exchange Ordinance 1969, Securities and Exchange Commission Rules 1987 and the regulations of Dhaka / Chittagong Stock Exchanges. They are also responsible for taking reasonable measures to safeguard the assets of the Company, and in that context to have proper regard to the establishment of the appropriate system of internal control with a view to preventing and detecting fraudulent activities and other irregularities.

The Directors are of the view that these financial statements have been prepared under the generally accepted accounting principles and in accordance with the International Accounting Standards as laid down by the Institute of Chartered Accountants of Bangladesh.


Directors endeavor to ensure that the Company maintains sufficient records to be able to disclose, with reasonable accuracy, the financial position of the Company and to be able to ensure that the financial statement of the Company meet with the requirement of the Company's Act 1994, International Accounting Standards and the regulations of the Dhaka / Chittagong Stock Exchanges.

The Directors have a reasonable expectation, after making enquiries and following a review of the Company's plan for the ensuing year including cash flows and borrowing facilities, that the Company has adequate resources to continue in operational existence for the foreseeable future, and therefore continues to adopt the going concern basis in preparing the accounts.

M/S. Toha Khan Zaman & Co., Chartered Accountants, Auditors of the Company have examined the financial statements made available by the Board of the Directors together with relevant financial record, related data, minutes of the Shareholders and Directors meeting and expressed their opinion in their report.

By order of the Board,

**Beacon Pharmaceuticals Limited,**



**Mohammad Ebadul Karim**  
Managing Director

# Belsar

10 mg  
20 mg  
40 mg

Tablet

Olmesartan Medoxomil USP

*24 hours optimum blood pressure control*



**Manufactured with-**

- ✓ **COS grade** API imported from **Mylan Laboratories Ltd.**  
Ensures Better Efficacy



**Available in Calendar Packaging**  
Ensures patient compliance



*Also available as*

## Belsar-M

5/20 mg  
5/40 mg

Tablet

Amlodipine BP & Olmesartan Medoxomil USP

*For Powerful Glycemic Control &  
Superior Cardio Renal Protection...*

# Sinjard

10 mg | 25 mg | Tablet

## Empagliflozin



- ✓ **Manufactured with Empagliflozin API from US FDA approved source**  
*Ensures Better Efficacy*
- ✓ **Available in Calendar Packaging (7's strip)**  
*Ensures Patient Compliance*

*Also available as*

**Sinjard-L**  $\frac{5/10 \text{ mg}}{5/25 \text{ mg}}$  Tablet  
Linagliptin & Empagliflozin

**Sinjard-M 500**  
Empagliflozin & Metformin 5/500 mg Tab.

# FINANCIAL STATEMENTS





# Independent Auditors' Report To The Shareholders of

## Beacon Pharmaceuticals Limited

### REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

#### Opinion:

We have audited the financial statements of **Beacon Pharmaceuticals Limited** (DVC: 2210270264AS621963) (hereinafter referred to as the 'Company'), which comprises the statement of financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view of the financial position of the company as at 30 June 2022, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) and other applicable laws and regulations.

#### Basis for Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key Audit Matters:

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

#### Property, Plant & Equipment:

See Note 4.00 to the financial statements:

#### The key audit matter

Property, Plant & Equipment are shown in the financial statement at written down value (Cost less Accumulated depreciation) as per IAS 16.

Depreciation on Property, Plant & Equipment has been charged at specified rates as per previous practice.

During the year, the company has made an adjustment of Property, Plant & Equipment amounting to Tk.12,393,908.

#### Our response to the key audit matter

Our audit procedures were designed to verify the individual assets; additions during the year etc. with the assets register which is maintained by software.

Physical inventory was carried out by the management at the year end and we were provided with regarding the physical existence of assets.

# Independent Auditors' Report To The Shareholders of Beacon Pharmaceuticals Limited

## Valuation of Inventories:

See Note 7.00 to the financial statements:

The key audit matter	Our response to the key audit matter
<p>Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2.</p> <p>Cost of inventories are determined on weighted average cost basis. Physical verification of inventories was carried out by inventory team (Internal Audit Team) consisting of management staff.</p>	<p>Our audit procedures were designed to verify the management's assumptions applied in calculating the value of inventory.</p> <p>We were supplied inventory certificate showing the value of the inventory as on 30 June 2022.</p> <p>We are to depend on the valuation certificate on the basis of physical inventory carried out by the inventory team formed by the management.</p>

## Recognition of Deferred Tax Assets:

See Note 10.00 to the financial statements:

The key audit matter	Our response to the key audit matter
<p>The Company reported net deferred tax assets total Tk.140,640,635 as at 30 June 2022.</p> <p>Significant judgment is required in relation to deferred tax assets as their recoverability is dependent on forecasts of future profitability over a number of years.</p> <p>We have determined this to be a key audit matter, due to the inherent uncertainty in forecasting the amount and timing of future taxable profits and the reversal of temporary differences.</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax assets and the assumptions used in estimating the Company's future taxable income.</p> <p>We also assessed the completeness and accuracy of the data used for the estimations of future taxable income.</p> <p>We involved tax specialists to assess key assumptions, controls, recognition and measurement of deferred tax assets.</p> <p>We also assessed the appropriateness of presentation of disclosures against IAS 12 Income Tax.</p>

# Independent Auditors' Report To The Shareholders of Beacon Pharmaceuticals Limited

## Revenue Recognition – Net Turnover:

See Note 28.00 to the financial statements:

### The key audit matter

At the year end the company reported total revenue of Tk.8,022,736,306.

Revenue is measured net of discounts, incentives and rebates earned by customers on the Company's sales. Within a number of the Company's markets, the estimation of discounts, incentives and rebates recognized based on sales made during the year is material and considered to be complex and judgmental. Therefore, there is a risk of revenue being misstated as a result of faulty estimations over discounts, incentives and rebates.

There is also a risk that, revenue may be overstated due to fraud through manipulation of the discounts, incentives and rebates recognized resulting from the pressure local management may feel to achieve performance targets.

### Our response to the key audit matter

We conducted substantive testing of revenue recorded over the year using sampling techniques, by examining the sales statements received from depots which have been accounted for through journal entries.

## Other Information:

Management is responsible for the other information. The Annual Report is expected to be made available to us after the date of this auditors' report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified when it becomes available to us and include the same in our report if those are received before preparation of this report.

## Responsibilities of Management and those Charged with Governance for the Financial Statements and Internal Controls:

Management is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards, and for such internal controls as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group and the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

# Independent Auditors' Report To The Shareholders of Beacon Pharmaceuticals Limited

## Auditor's Responsibilities for the Audit of the Consolidated and Separate Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also :

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

# Independent Auditors' Report

## To The Shareholders of

---

### Beacon Pharmaceuticals Limited


#### Report on other Legal and Regulatory Requirements:

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) The statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) The expenditure incurred was for the purposes of the Company's business.

The engagement partner on the audit resulting in this independent auditor's report is Md. Waliuzzaman, FCA

Dated, Dhaka  
26-October-2022

  
(Toha Khan Zaman & Co.)  
Chartered Accountants  
(DVC: 221070264AS621963)

**Beacon Pharmaceuticals Limited**  
**Statement of Financial Position**  
**As at 30 June 2022**

Particulars	Notes	Amount in Taka	
		30 June 2022	30 June 2021
<b>ASSETS:</b>			
<b>Non-Current Assets:</b>		<b>4,371,681,590</b>	<b>3,319,776,214</b>
Property, Plant & Equipments	4.00	3,072,097,332	2,881,685,287
Capital Work in Progress	5.00	1,298,558,085	437,216,157
Investment in Shares	6.00	1,026,173	874,770
<b>Current Assets:</b>		<b>6,444,215,802</b>	<b>5,215,795,475</b>
Inventories	7.00	1,971,935,593	1,278,652,519
Accounts Receivable	8.00	1,964,121,286	1,933,404,526
Advance, Deposit & Pre-payments	9.00	1,162,267,738	1,016,340,954
Advance Income Tax		138,365,246	-
Deferred Tax Assets	10.00	140,640,635	239,978,713
Short Term Loan	11.00	522,230,120	403,706,995
Investment in FDR	12.00	6,157,794	5,872,256
Cash & Cash Equivalents	13.00	538,497,391	337,839,512
<b>TOTAL ASSETS:</b>		<b>10,815,897,392</b>	<b>8,535,571,691</b>
<b>EQUITY &amp; LIABILITIES:</b>			
<b>Shareholders' Equity:</b>		<b>5,943,850,486</b>	<b>5,355,162,953</b>
Share Capital	14.00	2,310,000,000	2,310,000,000
Reserve and Surplus	15.00	1,231,058,381	1,413,765,843
Available for Sale Reserve		(1,651,251)	(1,802,654)
Retained Earnings	16.00	2,404,443,357	1,633,199,764
<b>Non-Current Liabilities:</b>		<b>197,914,365</b>	<b>387,746,624</b>
Long Term Loan	17.00	197,914,365	387,746,624
<b>Current Liabilities:</b>		<b>4,674,132,541</b>	<b>2,792,662,114</b>
Current Portion of Long Term Loan	18.00	216,014,430	225,895,398
Short Term Loan	19.00	3,413,052,320	1,883,561,131
Share Application Money Refundable	20.00	4,323,613	4,323,613
Accounts Payables	21.00	234,275,663	215,849,663
Accrued Expenses	22.00	74,299,265	100,287,491
VAT Payable	23.00	56,668,148	11,250,237
Liabilities for EWF & WPPF	24.00	66,048,369	58,577,255
Liability for Employees Medical Support Fund	25.00	3,052,980	
Provision for Employee's Provident Fund	26.00	30,285,304	23,003,728
Provision for Gratuity	27.00	105,329,468	80,309,165
Income Tax Payable	28.00	306,111,342	(2,098,102)
Dividend Payable	29.00	164,671,640	191,702,535
<b>TOTAL EQUITY &amp; LIABILITIES:</b>		<b>10,815,897,392</b>	<b>8,535,571,691</b>

**Net Assets Value per Share (par value Tk. 10 each)** 44.00 25.73 23.18


1.00 Annexed notes form part of the accounts.

2.00 Figures have been rounded off to the nearest taka.

3.00 Previous year's figure has been rearranged for comparison.



Company Secretary




Managing Director

  
Chairman

Signed in terms of our separate report of even date annexed

Dated, Dhaka  
26-October-2022

  
(Toha Khan Zaman & Co.)  
Chartered Accountants  
(DVC: 221070264AS621963)

## Beacon Pharmaceuticals Limited

# Statement of Profit & Loss and Other Comprehensive Income

## For the year ended 30 June 2022

Particulars	Notes	Amount in Taka	
		30 June 2022	30 June 2021
Net Turnover	30.00	8,022,736,306	7,121,152,785
Less: Cost of Goods Sold	31.00	3,875,791,274	3,434,422,533
<b>Gross Profit</b>		<b>4,146,945,032</b>	<b>3,686,730,252</b>
<b>Less: Operating Expenses:</b>			
Administrative Expenses	32.00	465,375,613	373,198,648
Marketing, Selling & Distribution Expenses	33.00	1,999,659,878	1,891,907,879
<b>Total Operating Expenses:</b>		<b>2,465,035,491</b>	<b>2,265,106,526</b>
<b>Operating Profit:</b>		<b>1,681,909,541</b>	<b>1,421,623,726</b>
Less: Financial Expenses	34.00	339,380,959	166,796,221
<b>Net Profit after Financial Expenses:</b>		<b>1,342,528,582</b>	<b>1,254,827,505</b>
Income from Other Sources	35.00	15,087,567	3,243,677
<b>Net Profit before contribution to WPPF</b>		<b>1,357,616,149</b>	<b>1,258,071,182</b>
Less: Contribution to WPPF	36.00	64,648,388	59,908,152
<b>Net Profit before Tax:</b>		<b>1,292,967,761</b>	<b>1,198,163,031</b>
Less: Provision for Current Income Tax		258,593,552	269,586,682
Add: Deferred Tax (Income)/Expense		99,338,078	65,407,054
<b>Net profit after tax for the year</b>		<b>935,036,130</b>	<b>863,169,294</b>
Other Comprehensive Income		-	-
<b>Net profit after tax for the year</b>		<b>935,036,130</b>	<b>863,169,294</b>
<b>Item that may be reclassified to profit or loss:</b>			
Unrealized Profit (loss) on quoted shares	37.00	151,403	248,025
<b>Total comprehensive income for the year</b>		<b>935,187,533</b>	<b>863,417,319</b>
<b>No. of Shares</b>	<b>14.00</b>	<b>231,000,000</b>	<b>231,000,000</b>
<b>Earning Per Share (par value Tk. 10 each)</b>	<b>38.00</b>	<b>4.05</b>	<b>3.74</b>


1.00 Annexed notes form part of the accounts.

2.00 Figures have been rounded off to the nearest taka.

3.00 Previous year's figure has been rearranged for comparison.



Company Secretary



Managing Director

Nurun Nahar Karim  
Chairman

Signed in terms of our separate report of even date annexed

Dated, Dhaka  
26-October-2022

Toha Khan Zaman & Co.  
Chartered Accountants  
(DVC: 221070264AS621963)

**Beacon Pharmaceuticals Limited**  
**Statement of Changes in Equity**  
**For the year ended 30 June 2022**

Amount in Taka

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Available for Sale Reserve	Retained Earning	Total Equity
Balance at the beginning of the year	2,310,000,000	1,408,262,744	5,503,099	(1,802,654)	1,633,199,764	5,355,162,953
Prior year Over adjustment of Foreign Exchange Loss.	-	-	-	-	-	-
Tax holiday reserve transferred to Retained Earnings			(5,503,099)	-	5,503,099	-
Net Profit transferred from Income Statement	-	-	-	-	935,036,130	935,036,130
Unrealized gain on quoted shares	-	-	-	151,403	-	151,403
Dep. Adjustment on Revaluation Reserve		(221,505,454)			221,505,454	-
Deferred Tax on Revaluation Adj.	-	44,301,091	-	-	(44,301,091)	-
Cash Dividend	-	-	-	-	(346,500,000)	(346,500,000)
<b>Balance at the end of the year</b>	<b>2,310,000,000</b>	<b>1,231,058,381</b>	<b>-</b>	<b>(1,651,251)</b>	<b>2,404,443,357</b>	<b>5,943,850,487</b>

**For the year ended 30 June 2021**

Amount in Taka

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Available for Sale Reserve	Retained Earning	Total Equity
Balance at the beginning of the year	2,310,000,000	1,583,657,104	5,503,099	(2,050,679)	733,236,109	4,630,345,633
Prior year adjustment against Foreign Exchange Loss	-	-	-	-	-	-
Net Profit transferred from Income Statement	-	-	-	-	863,169,294	863,169,294
Unrealized gain on quoted shares	-	-	-	248,025	-	248,025
Dep. Adjustment on Revaluation Reserve	-	(225,233,087)	-	-	225,233,087	-
Deferred Tax on Revaluation Adj.	-	49,838,727	-	-	(49,838,727)	-
Cash Dividend	-	-	-	-	(138,600,000)	(138,600,000)
<b>Balance at the end of the year</b>	<b>2,310,000,000</b>	<b>1,408,262,744</b>	<b>5,503,099</b>	<b>(1,802,654)</b>	<b>1,633,199,764</b>	<b>5,355,162,953</b>

1.00 Annexed notes form part of the accounts.

2.00 Figures have been rounded off to the nearest taka.


3.00 Previous year's figure has been rearranged for comparison.



Company Secretary




Managing Director

  
Chairman

Signed in terms of our separate report of even date annexed

Dated, Dhaka  
26-October-2022

  
(Toha Khan Zaman & Co.)  
Chartered Accountants  
(DVC: 221070264AS621963)

**Beacon Pharmaceuticals Limited**  
**Statement of Cash Flows**  
**For the year ended 30 June 2022**

Particulars	Notes	Amount in Taka	
		30 June 2022	30 June 2021
<b>A) Cash Flows from Operating Activities:</b>			
Collection from Customers		7,992,019,546	6,247,372,126
Cash paid to Suppliers & others		(6,119,717,890)	(5,866,712,187)
Interest paid		(339,380,959)	(166,796,221)
Income tax paid		(450,745,297)	(17,306,247)
<b>Net Cash Generated from Operations</b>	<b>42.01</b>	<b>1,082,175,400</b>	<b>196,557,471</b>
<b>B) Cash Flows from Investing Activities:</b>			
Acquisition of Property, Plant and Equipment		(1,719,241,463)	(313,408,023)
Short term Investment Received/(Paid)		(118,523,125)	(403,706,995)
Investment in FDR		-	-
Interest and Other Received		-	3,243,677
<b>Net Cash from/(used in) Investing Activities:</b>		<b>(1,837,764,588)</b>	<b>(713,871,341)</b>
<b>C) Cash Flows from Financing Activities:</b>			
Dividend paid		(373,530,895)	(59,417,965)
Long term Loan Received/(Paid)		(199,713,227)	(33,269,361)
Short term loan Received/(Paid)		1,529,491,189	349,059,869
<b>Net Cash from/(used in) Financing Activities</b>		<b>956,247,066</b>	<b>256,372,543</b>
<b>D) Net Increase/(decrease) in Cash and Cash Equivalents (A+B+C)</b>		<b>200,657,878</b>	<b>(260,941,327)</b>
<b>E) Opening Cash and Cash Equivalents</b>		<b>337,839,512</b>	<b>598,780,839</b>
<b>F) Closing Cash and Cash Equivalents (D+E)</b>	<b>13.00</b>	<b>538,497,390</b>	<b>337,839,512</b>
<b>Net Operating Cash Flows per Share (par value Tk. 10 each)</b>	<b>44.00</b>	<b>4.68</b>	<b>0.85</b>

1.00 Annexed notes form part of the accounts.  
2.00 Figures have been rounded off to the nearest taka.  
3.00 Previous year's figure has been rearranged for comparison.


  
Company Secretary

  
Managing Director

  
Chairman

Signed in terms of our separate report of even date annexed

Dated, Dhaka  
26-October-2022

  
(Toha Khan Zaman & Co.)  
Chartered Accountants  
(DVC: 221070264A5621963)

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**1.00 BACKGROUND AND ACTIVITIES OF THE COMPANY:**

**1.01 Background of the Company:**

The company was incorporated on 12 September 2001 as a Private Limited Company and subsequently converted into Public Limited Company on February 25, 2008 under the Companies Act, 1994 vide registration No. C-43991(531)/2001 dated 12 September 2001. The Company went for Initial Public Offering (IPO) in 2010. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited since the year 2010.

**1.02 Address of the Registered and Corporate Office:**

The registered office of the company is located at its factory premises at Kathali, Bhaluka, Mymensingh and corporate office address is located at 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223.

**1.03 Nature of Business Activities:**

The company is engaged in manufacture and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) Fluids, Active Pharmaceuticals Ingredients (APIs), Bio-tech products and genetic engineering products which the company sales in the local markets as well as international markets. The company also provides contract manufacturing and tool manufacturing services.

**1.04 Production Unit:**

Production unit of the company is situated at Kathali, Bhaluka, Mymensingh.

**2.00 SIGNIFICANT ACCOUNTING POLICIES:**

**2.01 Basis of Preparation and Presentation of the Financial Statements:**

The Financial Statements have been prepared and the disclosures of information made in accordance with the requirements of the Companies Act 1994, the Securities and Exchange Rules 1987, the Listing Regulations of Dhaka Stock Exchange as applicable and IASs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), International Financial Reporting Standard (IFRS) as applicable to the company. The Statement of Profit or Loss And Other Comprehensive Income have been prepared according to IAS 1 'Presentation of Financial Statements' based on accrual basis of accounting consistently applied following going concern assumption under generally accepted accounting principles and practices in Bangladesh. Statement of Cash Flows has been prepared on direct method in accordance with IAS 7.

**2.02 Accounting Convention and Assumption:**

The financial statements have been prepared under the historical cost convention as modified to include the revaluation of certain fixed assets which are stated at revalued amount. Accordingly, historical cost is employed to determine the monetary amounts at which the elements of the financial statements are to be recognized and carried in the statement of financial position and statement of profit or loss and other comprehensive income.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.03 Principle of Accounting Policies:**

The specific accounting policies have been selected and applied by the company's management for significant transactions and events that have a material effect within the Framework for the preparation and presentation of Financial Statements. Financial Statements have been prepared and presented in compliance with applicable IASs. Previous year's figures were re-arranged where necessary to conform current years' presentation. There were no significant changes in the accounting policies and valuation policies affecting the financial position and performance of the company. However, changes (as applicable) made to the presentation are explained into the note for the respective items.

**2.04 Application of accounting Standards:**

The following IASs and IFRSs are applicable to the financial statements for the year under review:

IAS	1 Presentation of Financial Statements
IAS	2 Inventories
IAS	7 Cash Flow Statements
IAS	8 Accounting Policies, Changes in Accounting Estimates and Errors
IAS	10 Events after the Balance Sheet Date
IAS	12 Income Tax
IAS	16 Properties, Plant and Equipment
IAS	19 Employee Benefits
IAS	21 The Effects of Changes of Foreign Exchange Rates
IAS	23 Borrowing Costs
IAS	24 Related Parties Disclosure
IAS	33 Earnings Per Share
IAS	36 Impairment of Assets
IAS	37 Provisions, Contingent Liabilities and Contingent Assets
IAS	39 Financial Instruments: Recognition and Measurement
IFRS	15 Revenue from Contracts with Customers
IFRS	9 Financial Instruments
IFRS	13 Fair Value Measurements

**2.05 Valuation of Inventories:**

Inventories are stated at the lower of cost or net realizable value in compliance with the requirements of Para 21 and 25 of IAS 2.

<b><u>Category of Stocks</u></b>	<b><u>Basis of Valuation</u></b>
Raw Materials and Packing Materials	: Moving average (weighted) cost
Work in Process	: Actual Cost
Finished Goods	: Actual Cost
Others	: Actual Cost

Cost comprises of the value of materials and attributable direct labor, depreciation and production overheads. The management has conducted annual physical verification of inventories on the closing date of business as on 30 June 2022 made valuation thereof on the basis stated above.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.06 Statement of Cash Flows:**

Statement of Cash Flows is prepared principally in accordance with IAS 7 'Statement of Cash Flows' and the cash flows from operating activities have been presented under direct method as required by the Securities and Exchange Rules 1987 and Considering the provisions that "Enterprises are Encouraged to Report Cash Flow From Operating Activities Using the Direct Method".

**2.07 Accounting Policies, Changes in Accounting Estimates and Errors:**

As per IAS 8 The preparation of financial Statements in conformity with the International Accounting Standards requires management to make judgment to estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statement.

During the year under review no remarkable change were made that make judgment to estimates and assumptions that affect the application of accounting policies reported amounts of assets, liabilities, income and expenses.

**2.08 Taxation:**

**2.08.01 Current Tax:**

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. The company makes provision for income tax as per requirement of the Income Tax Ordinance 1984. The applicable tax rate of the Company is 20.00% or 0.60 percent of Gross Receipt whichever is higher as per provision of section 82C of the Income Tax Ordinance 1984. Income tax return of the company for the assessment year 2021-2022 has been completed but necessary provision for unpaid taxes has not been made.

**Deferred Tax:**

During the year provision for Deferred Tax as per requirement by IAS 12 has been accounted for in the financial statements. Deferred tax is recognized using the balance sheet method. Deferred tax arises due to temporary difference deductible or taxable for the events or transactions recognized in the statement of profit or loss and other comprehensive income. A temporary difference is the difference between the carrying amounts of assets and liabilities and its tax base amount in the statement of financial position. Deferred tax asset or liability is the amount of income tax recoverable or payable in future period(s) recognized in the current period. The deferred tax asset/income or liability/expense do not create a legal liability/recoverability to and from the income tax authority. Deferred tax also arises due to revaluation of property, plant and equipment. The resulting impact of deferred tax assets/liabilities on revaluation surplus is included in the statement of changes in equity.

**2.09 Property, Plant and Equipment:**

Item of property, plant & equipment is recognized in accordance with IAS 16 Property, Plant and Equipment where it is probable that future economic benefits will flow to the entity and their cost can be measured reliably.

**2.09.01 Measurement and recognition:**

An item of property, plant & equipment qualifying for recognition is initially measured at its cost. Cost comprises: Purchase price, including all non recoverable duties and taxes but net off discount; and costs directly attributable to bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by the management.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.09.02 Subsequent costs:**

Repairs and maintenance expenditure is recognized as expenditure when incurred. Replacement parts are capitalized, provided that the original cost of the items they replace is derecognized.

**2.09.03 Disposal of property, plant and equipment:**

An item of property, plant and equipment is removed from the statement of financial position when it is disposed of or when no future economic benefits are expected from its use or disposal. The gain or loss on the disposal of an item of property, plant and equipment is included in the statement of income of the period in which the assets are disposed off. There were no disposals of property, plant and equipment in 2021.

**2.09.04 Impairment of Assets:**

In compliance with the requirements of IAS 36, Impairment of Assets, the carrying amount of non-financial assets, other than inventories are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the assets recoverable amount is estimated and impairment losses are recognized in profit and loss account. No such indication of impairment has been raised till to date.

**2.09.05 Depreciation of Fixed Assets:**

Depreciation is providing on Straight-line method. Depreciation is charged on additions according to para 55 of IAS 16.

The depreciation /amortization rate(s) are as follows which are in conformity with previous year:

Category of Fixed Assets	Rate %
Land & Land Development	0
Building	5
Vehicles	20
Electrical Installations	10
Office Equipment	10
Production Machinery & Equipment	15
Furniture & Fixture	10

**2.10 Leases:**

In compliance with the requirements of IAS 17 no financial and operating leases is accounted for during the year under review.

**2.11 Revenue Recognition:**

In compliance with the requirements of IFRS 15 Revenue, Revenue is recognized only when; Revenue receipts from customers against sales are recognized when products are dispatched to the customers, that is, when the significant risk and rewards of ownership have been transferred to the buyer recovery of the consideration is probable, the associated cost and possible return of goods can be estimated reliable and there is no continuing management involvement with the goods. Interest income is accounted for on accrual basis as per bank statement received from bank. Income is derived this year from export of finished products.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.12 Employee Benefits (IAS 19):**

The Company maintains both defined contribution plan (Provident Fund) and a retirement benefit obligation (Gratuity Fund) for its eligible permanent employees.

**2.13 Benefit Plans:**

**2.13.01 Defined Benefit Plans (Provident Fund):**

Defined contribution plan is a post-employment benefit plan under which the Company provides benefits for all of its permanent employees. The recognized Employees' Provident Fund is being considered as defined contribution plan as it meets the recognition criteria specified for this purpose. All permanent employees contribute 10% of their basic salary to the provident fund and the Company also makes equal contribution. This fund is recognized by the National Board of Revenue (NBR), under the First Schedule, Part B of Income Tax Ordinance 1984.

**2.13.02 Retirement Benefit Obligation (Gratuity Fund):**

The Company has a gratuity scheme, which covers all of its permanent employees. The gratuity is payable when the employees have completed minimum five years of service. Employees, leaving the employments after five completed years shall receive one month's terminal basic for each completed year.

**2.13.03 Contribution to workers' profit participation fund:**

As per section 234(1)(b) of Bangladesh Labor Act 2006 (as amended in 2013) 5% of the net profit of each year, not later than nine (9) months from the close of that period, is required to be transferred to the Fund, the proportion of the payment to the Participation Fund and the Welfare Fund being 80:10. The remaining 10% of the amount of net profit shall be paid by the Company to the Workers' Welfare Foundation Fund, as formed under the provision of the Bangladesh Worker's Welfare Foundation Act, 2006. Of the 80% being transferred to the participation fund, two-third has to be distributed in equal proportions to all the members (beneficiary) of the fund in cash and one-third has to be invested in accordance with the manner as stated in section 242 of that Act.

**2.14 Financial Instruments:**

**2.14.01 Initial recognition and subsequent measurement:**

A financial instrument is any contract that gives rise to financial assets of one entity and a financial liability or equity instrument of another entity. Financial assets include available for sale assets, held to maturity assets, held for trading, loans and receivable and cash and cash equivalent. Financial Liabilities include borrowings, others financing and bank loans and accounts payables.

**2.14.02 Recognition:**

An entity recognizes financial assets or liabilities in its statement of financial position when and only when the entity becomes a party to the contractual provision of the instrument.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.14.03 Subsequent Measurement:**

Asset Category	Description	Measurement after initial recognition	Recognition
Available for sale Financial assets: 1) Investment in marketable securities	Financial assets that are either electively designated into the category or do not fall into any other category	Fair Value	1) realized gain loss/dividend income/Interest income to statements of comprehensive income. 2) Unrealized gain-loss to Statement of Comprehensive Income.
Loans and Receivables, 1) Trade Receivables 2) Others receivables	unquoted financial assets with fixed or determinable payments.	Authorized Cost	Realized gain loss/interest income foreign currency gain loss to statement of Comprehensive Income
Financial liabilities at cost /amortized cost. 1)Short term loan, 2)Trade creditors, 3) Others payable	All financial liabilities other than those at fair value through profit and loss	Authorized Cost	Realized gain loss/interest income foreign currency gain loss to statement of Comprehensive Income

**2.15 The Effects of Changes of Foreign Exchange Rates:**

Foreign currency transactions are recorded at the rates applicable on the date of transaction in accordance with IAS-21 (The Effects of Changes in Foreign Exchange Rates). Gains or losses out of foreign currency transactions are charged/credited to the profit and loss account whenever arises. This year the company made transactions in foreign currency for import of machineries which has been accounted for properly.

**2.16 Credit Risk:**

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The senior management of **Beacon Pharmaceuticals Limited** carefully manages its exposure to credit risk. Credit exposures arise principally in receivables from customers into **Beacon Pharmaceuticals Limited** asset portfolio. The credit risk management and control are controlled through the credit policies of **Beacon Pharmaceuticals Limited** which are updated regularly. The company is also exposed to other credit risks arising from balances with banks which are controlled through board approved counterparty limits.

**2.17 Liquidity Risk:**

Liquidity risk is defined as the risk that the Company will not be able to settle or meet its obligations on time or at a reasonable price. The Company's approach toward managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.18 Interest Rate Risk:**

Interest rate risk is the risk that company faces due to unfavorable movement in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/investments tend to increase the interest rates. Such rises in interest rates mostly affect companies having floating rate loans or companies investing in debt securities.

**2.19 Exchange Rate Risk:**

Exchange rate risk occurs due to changes in exchange rates. As the company imports equipment from abroad, unfavorable volatility or currency fluctuation may affect the profitability of the Company. When exchange rate increase against local currency, opportunity arises for generating more profit.

**2.20 Market Risks:**

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

**2.21 Borrowing Costs:**

In compliance with the requirements of IAS-23 'Borrowing Costs' borrowing costs of operational period on short-term loan and overdraft facilities from Banks was charged off as revenue expenditure as those were incurred.

**2.22 Related Parties disclosure:**

In compliance with the requirements of IAS 24, the company carried out a number of transactions with related parties in the normal course of business. Related party disclosures have been made in a separate note to the accounts.

**2.23 Earning per Shares:**

**2.23.01 Basic Earnings Per Share:**

The company calculates Basic earning of share (EPS) in according with IAS 33 'Earning per Shares' which has been shown on the face of Income Statement. The same has been calculated dividing surplus available for ordinary shareholders by weighted number of ordinary shares outstanding at the end of the year.

**2.23.02 Diluted Earnings Per Share:**

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the affects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant periods.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**2.24 Provision:**

The preparation of financial statements in conformity with International Accounting Standards (IAS) 37 provides that, Provisions, Contingent Liabilities and Contingent Assets requires management to make estimates and assumption that affect the reported amounts of revenues and expense, assets and liabilities, and the disclosure requirements for contingent assets and liabilities during and at the date of the financial statements.

In accordance with the guidelines as prescribed by IAS 37 provisions were recognized in the following situations. When the company has represent obligation as a result of past event. When it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation ; and realizable estimate can be made of the amount of the obligation.

Provisions in the financial statements at an appropriate level are not done with regard to an adequate provision of risks and uncertainties. An amount recorded as a provision represents the best estimate of the probable expenditure required fulfilling the current obligation on the balance sheet date.

**2.25 Intangible Assets:**

In compliance with requirements of IAS 38 intangible assets are usually absorbed as revenue charges as and when incurred. The Company has no intangible assets written off during the year under review.

**2.26 Cash and Cash Equivalents:**

Cash and Cash Equivalents include cash in hand, cash at banks, etc. which are available for use by the company without any restrictions. There is an insignificant risk of change in value of the same.

**2.27 Trade and Other Payable:**

Liabilities are recorded at the amount payable for settlement in respect of goods and services received by the company.

**2.28 Repairs and Maintenance Charges:**

These are usually charged out as revenue expenditure in the period in which it is incurred.

**2.29 Bad and doubtful debts:**

No provision for bad and doubtful debts has been made since sales/export are realizable.

**2.30 Promotional Expenses:**

All costs associated with promotional activities are charged in the year those were incurred like sample issued.

**2.31 Insurance Coverage:**

Fixed Assets and Inventories of the company are covered by general insurance policies.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

**3.00 COMPLIANCE AND OTHERS:**

**3.01 Compliance with Local Laws:**

The Financial Statements have been prepared in compliance with requirements of the Companies Act 1994, the Securities and Exchange Rules 1987 and other relevant local laws and rules.

**3.02 Compliance with International Accounting Standards (IAS):**

The Financial Statements have been prepared in compliance with requirements of IAS/IFRS as adopted in Bangladesh.

**3.03 Reporting Currency and Level of Precision:**

The figures in the Financial Statements represent Bangladesh Currency (Taka), which have been rounded off to the nearest Taka except where indicated otherwise.

**3.04 Comparative Information:**

Comparative information have been disclosed in respect of the year 2021 for all numerical information in the Financial Statements and also for the narrative and descriptive information when it is relevant for understanding of the current period's Financial Statements.

**3.05 Events after the reporting period:**

In compliance with the requirements of IAS-10 "Events after the Reporting Period" post statement of financial position events that provide additional information about the Company's position at the statement of financial position date are reflected in the financial statements and events after the statement of financial position date that are not adjusting events are disclosed in the notes when material.

**3.06 Directors' responsibility statement:**

The Board of Directors takes the responsibility for the preparation and fair presentation of these financial statements.

**3.07 Reporting Period:**

The financial period of the company covers one year from 01 July 2021 to 30 June 2022 and followed consistently.

**3.08 Approval of Financial Statement:**

The financial statements have been approved by the Board of Directors as on 25 October 2022.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
04.00	PROPERTY PLANT & EQUIPMENT: Tk. 3,072,097,332			
	A) Cost:			
	Opening Balance		4,009,604,468	6,714,305,779
	Less: Adjustment for prior year error		-	2,900,236,269
	Restated Opening Balance		4,009,604,468	3,814,069,510
	Add: Addition during the year		636,158,626	219,006,285
	Add:Revaluation Surplus on Machinery		-	-
	Less: Adjustment during the year		12,393,908	23,471,327
	Closing Balance (A)		4,633,369,186	4,009,604,468
	B) Accumulated Depreciation			
	Opening Balance		1,127,919,181	3,666,470,783
	Less: Adjustment for prior year error		-	2,900,236,269
	Restated Opening Balance		1,127,919,181	766,234,514
	Add: Addition during the year		439,700,176	385,155,994
	Less: Adjustment during the year		6,347,503	23,471,327
	Closing Balance (B)		1,561,271,854	1,127,919,181
	Written Down Value (A-B)		3,072,097,332	2,881,685,287
	Details of Fixed Assets Schedule are given in Annexure-A			
5.00	CAPITAL WORK IN PROGRESS: Tk. 1,298,558,085			
	Opening Balance		437,216,158	342,814,419
	Add: Addition during the year	Notes-5.01	861,341,927	94,401,738
			1,298,558,085	437,216,157
	Less: Transfer to property plant & equipment		-	-
	Closing Balance		1,298,558,085	437,216,157
5.01	Breakup of Capital Work in Progress addition during the year: Tk. 861,341,927			
	Staff Dormitory		13,366,357	-
	R & D Building		101,678,158	6,042,478
	Parenteral Building		369,120,703	88,359,260
	Central Warehouse-Factory		261,815,508	-
	Central Service Building-Factory		103,738,354	-
	"Guard Dormitory Building-Factory"		5,306,667	-
	Seven Storied Central Canteen		6,316,180	-
			861,341,927	94,401,738
6.00	INVESTMENT IN SHARE: Tk. 1,026,173			
	Opening Balance		874,770	626,745
	Add: Unrealized gain or (Loss)		151,403	248,025
	Closing Balance		1,026,173	874,770

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

Breakup of the above amount is given below:

Particulars	Number of Shares	Market Value		Investment Value
		30 June 2022	30 June 2021	
R N Spinning Mills Limited	168,225	1,026,173	874,770	3,855,040
<b>Total</b>	<b>168,225</b>	<b>1,026,173</b>	<b>874,770</b>	<b>3,855,040</b>

The above amount have been classified as "Available for sale " financial assets as per IFRS 9 and shown at fair value of Tk. 1,026,173.00 derived from Quoted share prices as on 30-06-2022. Unrealized gain of Tk. 151,403.00 on the unsold shares has been recognized in the Statement of Profit or Loss and Other Comprehensive Income.

**7.00 INVENTORIES: Tk. 1,971,935,593**

Raw and Packing Materials	917,402,731	439,173,665
Laboratory Chemicals	5,226,839	137,720,147
Stores and Consumable others	82,525,140	-
Finished Goods	651,843,751	442,677,763
Work-in-Process	224,693,855	259,080,944
Stock in Transit	90,243,277	-
<b>Closing Balance</b>	<b>1,971,935,593</b>	<b>1,278,652,519</b>

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2. Cost of inventories are determined on weighted average cost basis. Physical verification of inventories was carried out by inventory team consisting management staff.

Sl. No.	Materials/Product	Unit	Quantity	Amount in Tk.
01	Raw Materials (Active)	KG	98,087	461,537,175
		GM	108,340	90,910,615
		MG	24	16,161
		Ltr	58	55,313,648
		MIU	3,000	2,768,880
		ML	30,146	23,360,917
		Pcs	1,197	13,355,237
Sub-Total:				647,262,633
02	Raw Materials (Excipient)	KG	188,872	73,535,612
		GM	111,445	353,315
		Ltr	1,867	2,796,365
		ML	17,539	15,419
		Pcs	71,724,344	19,136,310
Sub-Total:				95,837,021

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka		
			30 June 2022	30 June 2021	
	Sl. No.	Materials/Product	Unit	Quantity	Amount in Tk.
	03	Primary Packaging	KG	97,889	50,816,974
			Pcs	9,978,366	55,613,355
	Sub-Total:				106,430,329
	04	Secondary Packaging	GM	51,202	18,433
			PCS	42,112,778	67,854,316
	Sub-Total:				67,872,749
	05	Work in Process (WIP)	Pcs		224,693,855
	Sub-Total:				224,693,855
	06	Finished Goods	Pack		651,843,751
	Sub-Total:				651,843,751
	07	Laboratory Chemicals (Reagent)	GM	68,967	2,861,528
			KG	203	186,651
			Ltr	2,381	761,625
			ML	23,008	1,416,786
			Pack	9	250
	Sub-Total:				5,226,839
	08	Stores and Consumable Othes			82,525,140
	09	Stock in Transit			90,243,277
	Grand-Total:				1,971,935,594

**8.00 ACCOUNTS RECEIVABLE: Tk. 1,964,121,286**

Rangpur Sales Centre	30,405,452	29,339,427
Bogra Sales Center	15,968,580	16,049,857
Rajshahi Sales Centre	25,819,336	25,371,149
Jessore Sales Centre	25,184,767	25,151,094
Khulna Sales Centre	17,971,443	18,961,139
Barisal Sales Center	23,562,691	19,049,152
Faridpur Sales Centre	12,377,280	10,911,597
Mymensingh Sales Centre	17,120,972	15,872,876
Narayangonj Sales Centre	13,271,124	12,422,336
Comilla Sales Centre	32,118,724	37,995,435
Sylhet Sales Centre	23,834,001	27,303,170
Maizdee/Chowmuhony Sales Centre	28,248,210	25,236,088
Chittagong Sales Centre	19,830,502	18,202,428
Dinajpur Sales Centre	15,398,163	15,433,640

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Cox's Bazar Sales Center		27,221,623	29,447,900
	Tangail Sales Centre		4,356,240	7,316,468
	Beacon Privilege Point		24,810,106	27,735,654
	Dhaka Sales Centre/Dhaka North		39,342,296	92,326,530
	Dhaka Sales Center-Mohd. Pur Kakrail/Dhaka South		40,985,859	49,850,467
	Brahmanbaria Sales Centre		35,488,207	36,765,853
	Feni Sales Centre		14,441,892	14,859,936
	Beacon Medicare Limited		1,425,257,251	1,336,690,992
	Niketan Depot		21,435,961	22,019,761
	Pabna Sales Centre		17,660,167	17,163,355
	Chandpur Sales Centre		2,133,633	1,928,222
	Uttara Depot		9,876,806	
			<b>1,964,121,286</b>	<b>1,933,404,526</b>
	i) The above receivables are considered good by the management.			
	ii) The above amount is receivable from customers against credit sales.			
	iii) No amount was due from Directors, Managing Director and other officers of the company and any of them or jointly with any other person.			
	iv) The Accounts Receivables have no securities except their personal securities of buyers.			
<b>9.00</b>	<b>ADVANCE, DEPOSITS &amp; PREPAYMENTS: Tk. 1,162,267,738</b>			
	Advance against VAT	Note-9.01	-	3,505,856
	Advance to employees	Note-9.02	151,358,951	9,472,850
	Advance for Earnest Money & Security Deposit	Note-9.03	106,857,551	100,761,069
	Advance against Import	Note-9.04	235,622,633	462,151,289
	Advance L/C Margin	Note-9.05	64,952,895	86,860,510
	Other Advance	Note-9.06	408,724,848	120,588,413
	Advance agst Suppliers	Note-9.07	194,750,859	233,000,967
			<b>1,162,267,738</b>	<b>1,016,340,954</b>
<b>9.01</b>	<b>Advance against VAT &amp; Tax: Tk. 0</b>			
	VAT on Depot Stock		-	
	Advance against VAT		-	3,505,856
			-	<b>3,505,856</b>
<b>9.02</b>	<b>Advance to employees: Tk. 151,358,951</b>			
	Salary		467,702	352,410
	Marketing expense		117,096,401	(907,486)
	Advance against Motorcycle		18,590,266	243,928

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Mobile Set		15,083,298	9,783,998
	Advance - Marketing Expenses		121,284	-
			<b>151,358,951</b>	<b>9,472,850</b>
<b>9.03</b>	<b>Advance for Earnest Money &amp; Security Deposit: Tk. 106,857,551</b>			
	Earnest Money & Security Deposit - Tender		92,144,591	81,920,911
	Bank Guarantee against Titas Gas		7,825,800	7,825,800
	Security Deposit - Titas Gas		6,301,020	10,428,218
	Security Deposit - Electricity		56,140	56,140
	Security Deposit - T & T Board		30,000	30,000
	Security Deposit - CDBL		500,000	500,000
			<b>106,857,551</b>	<b>100,761,069</b>
<b>9.04</b>	<b>Advance against Import: Tk. 235,622,633</b>			
	Advance against Import		235,622,633	462,151,289
			<b>235,622,633</b>	<b>462,151,289</b>
<b>9.05</b>	<b>Advance against L/C Margin: Tk. 64,952,895</b>			
	Advance against L/C Margin		64,952,895	86,860,510
			<b>64,952,895</b>	<b>86,860,510</b>
<b>9.06</b>	<b>Other Advance: Tk. 408,724,848</b>			
	Advance against Office Space		28,238,343	65,967,520
	Advance against Depot Rent		8,314,197	8,299,857
	Advance against Land		372,172,308	46,321,036
			<b>408,724,848</b>	<b>120,588,413</b>
<b>9.07</b>	<b>Advance agst Suppliers: Tk. 194,750,859</b>			
	"Printing & Packing - Manufacturer"		1,390,416	-
	Machinery & Equipment		-	43,606,502
	Vehicle		(7,145,695)	44,638,677
	Construction & Engineering		26,535,052	-
	Spare & Parts		183,540	-
	Travel Agency		1,562,037	-
	Clearing & Forwarding House		19,758,433	53,884,618
	Miscellaneous		-	90,871,170
	Toll/ FG Supply		152,467,076	-
			<b>194,750,859</b>	<b>233,000,967</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	There is no aggregate amount due from Directors.			
	There is no claim against the Company, which can be acknowledged as bad debt.			
	No amount is due by the associated undertakings.			
10.00	DEFERRED TAX ASSET: Tk. 140,640,635			
	Opening Balance		239,978,713	305,385,767
	Deferred Tax (Income)/Expenses		99,338,078	65,407,054
	Closing Balance		140,640,635	239,978,713
	Deferred Tax (Income)/Expenses			
	The break up is given below:			
	Carrying amount			
	Fixed Assets (Excluding Land & Land Development)		2,447,995,029	2,315,620,713
	Provision for Gratuity		(105,329,468)	(80,309,165)
	Provision for Provident Fund		(30,285,304)	(23,003,728)
			2,312,380,257	2,212,307,820
	Tax Base:			
	Fixed Assets (Excluding Land & Land Development)		1,609,177,082	1,145,735,762
	Provision for Gratuity		-	-
			1,609,177,082	1,145,735,762
	Taxable /(deductible) temporary difference		703,203,175	1,066,572,058
	Tax rate		20.00%	22.50%
	Deferred tax (assets )/liabilities		140,640,635	239,978,713
	Less: Opening Balance		239,978,713	305,385,767
	Deferred tax( income)/expenses		99,338,078	65,407,054
	Deferred tax on revaluation surplus		-	-
	Deferred tax (income)/expenses for the year		99,338,078	65,407,054
11.00	Short Term Loan & Advance: Tk. 522,230,120			
	MEK Auto Bricks Limited		7,609,400	-
	MEK Pharmatech Limited		22,272,000	-
	Beacon Nutraceuticals Limited		22,702,611	-
	Beacon Oncology Limited		47,603,166	-
	Beacon Power Systems Limited		28,001,100	-
	"Beacon Cephalosporin Limited (New Cephalopirin)"		63,831,440	-
	Ereba Capsules Limited		51,800,000	403,706,995

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Beacon Medicare Limited		265,688,267	-
	Beacon Business Solution Limited		12,722,136	-
			<b>522,230,120</b>	<b>403,706,995</b>
<b>12.00</b>	<b>Investment in FDR: Tk. 6,157,794</b>			
	Rupali Bank Limited A/C: 0018035004648		6,157,794	5,872,256
			<b>6,157,794</b>	<b>5,872,256</b>
<b>13.00</b>	<b>CASH &amp; CASH EQUIVALENTS: TK. 538,497,391</b>			
	Cash in Hand	Note-13.01	9,915,727	89,201,096
	Cash at Bank	Note-13.02	528,581,664	248,638,416
			<b>538,497,391</b>	<b>337,839,512</b>
<b>13.01</b>	<b>Cash in Hand: Tk. 9,915,727</b>			
	Head Office		1,412,723	66,921,950
	Factory Office		4,399,592	5,140,415
	Chattagram Sales Office		358,390	1,755,540
	Mymensingh Sales Office		1,776	850,239
	Sylhet Sales Office		301,758	238,814
	Cumilla Sales Office		31,410	361,033
	Barishal Sales Office		345,511	49,689
	Faridpur Sales office		4,088	351,192
	Rangpur Sales Office		286,226	1,206,966
	Rajshahi Sales Office		275,363	186,995
	Narayanganj Sales Office		165,099	345,091
	Maizdee Sales Office		156,426	44,953
	Khulna Sales Office		1,631	1,228,728
	Bogura Sales Office		235,288	1,971,593
	Cox's Bazar Sales Office		17,625	1,359,609
	Dinajpur Sales Office		18,594	398,042
	Dhaka North Sales Office		603,362	2,825,318
	Dhaka South Sales Office		55,273	449,977
	Feni Sales Office		261,011	1,117,075
	B. Baria Sales Office		392,489	908,802
	Beacon Privilege Point Sales Office		2,329	25,003
	Jessore Sales Office		101,649	537,279
	Tangail Sales Office		210,381	448,796
	Niketon sales center		6,130	37,184
	Pabna Sales Office		82,405	352,444

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Chandpur Sales Office		1,202	212
	CDC		187,996	88,157
			<b>9,915,727</b>	<b>89,201,096</b>

Cash in hand is supported by cash custody certificate from the management.

**13.02 Cash at Bank: Tk. 528,581,664**

First Security Islamic Bank Limited CD A/C No. 1110001246	1,205,068	44,315
Janata Bank Limited CD A/C. No. - 1014203	84,557,996	5,761,008
Shahjalal Islami Bank Limited AWA A/C. No. 10078	10,552	10,552
ICB Islami Bank Limited Principal Br., CD A/C.No.001000200071157	757,163	81,483
Dutch Bangla Bank Limited CD A/C. No. 0105110000016107	15,383,892	18,643,310
Dutch Bangla Bank Limited STD A/C. No. 010511000001641	94,995,617	78,794,670
Rupali Bank Limited, Local Office Branch, Motijheel, Dhaka. CD A/C. 89649	1,518,022	1,518,517
Sonali Bank Limited, Dilkusha Corp. Branch, Motijheel, Dhaka. CD A/C. 33028459	1,732,221	22,039
Janata Bank Limited, Bhaluka Branch. STD A/C. 0000131	17,278	17,083
Janata Bank Limited FC A/C. 402000449	9,831,362	9,831,362
Dutch Bangla Bank Limited, CD A/C No. 105.110.28382	739,948	1,344,085
Eastern Bank Limited, Credit Card. A/C. No. 7260	(135,962)	(135,962)
Bank Asia Limited CD A/C. 04633000196	360,099	360,939
Commercial Bank of Ceylon PLC. A/C. # 1817000818	(1,287,586)	1,596,530
Commercial Bank of Ceylon, ERQ A/C. # 1802011076	22,248	299,042
"DBBL- Dividend- A/C-2271200000340 ( 2015-2016 )"	2,612,924	2,647,268
"DBBL-Dividend A/C 1051200003909 ( 2016-2017 )"	1,875,021	1,954,515
"DBBL - Dividend A/C 1051200004082 ( 2017-2018 )"	2,336,079	2,450,510
"DBBL- Dividend- A/C-1051200004173 ( 2018-2019 )"	3,544,262	3,658,706
"DBBL- Dividend- A/C-1051200004285 ( 2019-2020 )"	7,836,610	7,538,537
"DBBL- Dividend- A/C-1051200004404 ( 2020-2021 )"	511,223	-
Dutch Bangla Bank-CD-281-110-0003384 (Factory)	11,980,750	7,594,949
Brac Bank Limited CD-150-520-1786608001	450,475	488,005
Shimanto Bank Limited A/C: 410000140	96,895	96,895
Sonali Bank Limited, Foreign Exchange Br. CD A/C-20744	24,688,445	571,320
United Commercial Bank Limited CD-1041101705	26,044,951	1,535,988
Eastern Bank Limited, CD A/C. No. 9840	201,491,246	100,002,287
One Bank Limited CD A/C: 7313	1,570,336	1,574,026
Shahjalal Islami Bank Limited AWA A/C. No. 9440	8,959,251	-
Al Arafah Islami Bank Ltd, A/C-0151020056089	9,010,000	-
Dutch Bangla Bank Collection A/C (25 AC)	15,865,280	336,437
<b>Total Taka:</b>	<b>528,581,664</b>	<b>248,638,416</b>

Bank balances are either reconciled or agreed with the bank statements.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
14.00	SHARE CAPITAL: Tk. 2,310,000,000			
	Authorized Capital:			
	300,000,000 ordinary shares of Tk. 10 each		3,000,000,000	3,000,000,000
	Issued, Subscribed and Paid-up Capital:			
	231,000,000 ordinary shares of Tk. 10 each fully paid up		2,310,000,000	2,310,000,000
	Breakdown as follows :			
	Wholly Paid in cash 176000000 Shares @Tk.10		1,760,000,000	1,760,000,000
	Others than in cash 55000000 Shares @ Tk.10		550,000,000	550,000,000
			2,310,000,000	2,310,000,000

Shareholding Position was as follows:

Category of Shareholder	30 June 2022			30 June 2021		
	No. of Share	No. of Shareholders	% of Total Shares	No. of Share	No. of Shareholders	% of Total Shares
Sponsors/Directors	69,312,000	7	30%	69,312,000	7	30%
Institutions	78,646,215	181	34%	81,171,693	217	35%
Public	83,041,785	8,134	36%	80,516,307	9,531	35%
<b>Total Taka:</b>	<b>231,000,000</b>	<b>8,322</b>	<b>100%</b>	<b>231,000,000</b>	<b>9,755</b>	<b>100%</b>

The Sponsors/Directors Shareholding positions of the company are as under:

Name of Sponsors/Directors	Numbers of Shares	Amount in Taka	
		30 June 2022	30 June 2022
Mr. Md. Ebadul Karim	58,228,800	582,288,000	582,288,000
Mrs. Nurun Nahar Karim	4,725,000	47,250,000	47,250,000
Mr. Md Niazul Karim	6,354,000	63,540,000	63,540,000
Mrs. Rabeya Khatun	1,050	10,500	10,500
Mrs. Farzana Amin	1,050	10,500	10,500
Mr. Md. Akter Hossain	1,050	10,500	10,500
Mr. Md. Abul Khayer	1,050	10,500	10,500
<b>Total Taka:</b>	<b>69,312,000</b>	<b>693,120,000</b>	<b>693,120,000</b>

Classification of shareholders by holding:

Range of Holdings	Numbers of Shareholders	No. of Shares	% of holding 30 June 2022
Less than 501 Shares	3,953	715,881	0.31%
501 to 5,000 Shares	3,766	3,630,670	1.57%
5001 to 10,000 Shares	196	1,430,876	0.62%
10,001 to 20,000 Shares	137	1,945,150	0.84%

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

Range of Holdings	Numbers of Shareholders	No. of Shares	% of holding 30 June 2022
20,001 to 30,000 Shares	59	1,448,572	0.63%
30,001 to 40,000 Shares	35	1,216,336	0.53%
40,001 to 50,000 Shares	22	1,023,798	0.44%
50,001 to 100,000 Shares	50	3,840,270	1.66%
100,001 to 1,000,000 Shares	68	20,190,914	8.74%
Above 1,000,000 Shares	36	195,557,533	84.66%
<b>Total:</b>	<b>8,322</b>	<b>231,000,000</b>	<b>100%</b>

**15.00 RESERVE & SURPLUS: TK. 1,231,058,381**

Revaluation Reserve	Note-15.01	1,231,058,381	1,408,262,744
Tax Holiday Reserve	Note-15.02	-	5,503,099
<b>Closing Balance</b>		<b>1,231,058,381</b>	<b>1,413,765,843</b>

**15.01 Revaluation Reserve: Tk. 1,231,058,381**

Revaluation reserve has been created out by the amount of revaluation surplus of fixed assets.  
Details are shown below:

Particulars	Revaluation Surplus as on 01.07.2021	Revaluation Surplus during the year	Depreciation adjustment (Note-15.03)	Deferred tax on Depreciation Adjustment	Revaluation Reserve as on 30 June 2022
Land & Land Development	168,084,972	-	-	-	168,084,972
Building	10,152,852	-	1,072,484	214,497	9,294,864
Vehicles	-	-	-	-	-
Electrical Installation	-	-	-	-	-
Office Equipments	(7,787,386)	-	-	-	(7,787,386)
Machineries	1,244,344,116	-	220,432,970	44,086,594	1,067,997,740
Furniture & Fixtures	(6,531,810)	-	-	-	(6,531,810)
<b>Total:</b>	<b>1,408,262,744</b>	<b>-</b>	<b>221,505,454</b>	<b>44,301,091</b>	<b>1,231,058,381</b>

**15.02 Tax Holiday Reserve: Tk. 5,503,099**

**5,503,099**

Tax Holiday Reserve is being carried forward from 2010 now transferred to retained earnings.

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

**15.03 Revaluation Reserve Adjustment: Tk. 231,709,957**

Range of Holdings	Revaluation Surplus	Useful Life (Years)	Depreciation on Revaluation Surplus
Land & Land Development	168,084,972	-	-
Building	21,449,683	20.00	1,072,484
Vehicles	47,307,873	5.00	9,461,575
Electrical Installation	7,429,282	10.00	742,928
Office Equipment's	(7,787,386)	10.00	-
Machineries	1,470,287,911	6.67	220,432,970
Furniture & Fixture	(6,531,810)	10.00	-
<b>Total</b>	<b>1,700,240,525</b>	<b>-</b>	<b>231,709,957</b>

**16.00 RETAINED EARNINGS: Tk. 2,404,443,357**

Opening Balance		1,633,199,764	733,236,109
Less: Prior year adjustment for loss on foreign exchange fluctuations		-	-
Less: Dividend for the year 2020-2021		(346,500,000)	(138,600,000)
		1,286,699,764	594,636,109
Add: Net Profit during the year		935,036,130	863,169,295
		2,221,735,895	1,457,805,404
Add: Revaluation Reserve adjustment	Note-15.01	221,505,454	225,233,087
Add: Tax Holiday Reserve		5,503,099	
Less: Deferred Tax Adjustment on Rev.Adjustment		(44,301,091)	(49,838,727)
<b>Closing Balance</b>		<b>2,404,443,357</b>	<b>1,633,199,764</b>

**17.00 LONG TERM LOAN: Tk. 197,914,365**

Rupali Bank Limited	Note-17.01	197,914,365	382,237,770
BRAC Bank Limited	Note-17.02	-	5,508,854
<b>Closing Balance</b>		<b>197,914,365</b>	<b>387,746,624</b>

**17.01 Rupali Bank Ltd: Tk. 197,914,365**

Opening balance		598,252,200	624,267,442
Add: Received during the year		-	-
Add: Interest during the year		78,459,747	45,989,568
Less: Paid during the year		262,783,152	72,004,810
		413,928,795	598,252,200
Less: Transfer to current portion of long term loan		216,014,430	216,014,430
<b>Total</b>		<b>197,914,365</b>	<b>382,237,770</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Details are as under:			
	Limit Amount : Tk. 700,000,000			
	Purpose : Land & Land Development			
	Security : Land & Buildings			
	Interest Rate : 9% per annum			
	Mode of Payment : From own sources			
	Type of Facility : BMRE			
	Validity : UP to 2022			
	Nature of Security : Mortgage of Land, Buildings & Machineries			
<b>17.02</b>	<b>BRAC Bank Ltd: Tk. 0</b>			
	Opening balance		15,389,822	22,643,939
	Add: Adjustment/Received during the year		-	-
	Add: Interest during the year		624,197	1,968,918
	Less: Paid during the year		16,014,020	9,223,035
			-	15,389,822
	Less: Transfer to current portion of long term loan		-	9,880,968
	<b>Total</b>		-	<b>5,508,854</b>
	Details are as under:			
	Limit Amount : Tk. 40,000,000			
	Purpose : To procure total 22 nos. of vehicles			
	Security : Vehicles			
	Interest Rate : 9% per annum			
	Mode of Payment : From own sources			
	Type of Facility : Lease Finance			
	Validity : Up to 2022			
	Nature of Securities: Joint registration of Vehicles			
<b>18.00</b>	<b>CURRENT PORTION OF LONG TERM LOAN: Tk. 216,014,430</b>			
	Rupali Bank Limited		216,014,430	216,014,430
	BRAC Bank Limited		-	9,880,968
	<b>Total Taka:</b>		<b>216,014,430</b>	<b>225,895,398</b>
<b>19.00</b>	<b>SHORT TERM LOAN: Tk. 3,413,052,320</b>			
	LC/TR - First Security Bank Limited, Gulshan Branch, Dhaka	Note-19.01	9,355,640	111,300,865
	CC (Hypo)- Janata Bank Limited, Corporate Bhaban Branch	Note-19.02	1,431,567,705	1,396,842,780
	Janata Bank Ltd-WC Loan (Covid)	Note-19.03	424,364,110	-
	United Commercial Bank-Tejgaon Branch.	Note-19.04	320,190,742	202,786,013

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Standard Chartered Bank-Gulshan Branch	Note-19.05	6,950,852	72,631,473
	Eastern Bank Limited	Note-19.06	477,082,247	100,000,000
	Commercial Bank of Ceylon	Note-19.07	197,916,023	-
	Shahjalal Islami Bank Ltd	Note-19.08	545,625,000	-
	<b>Total Taka:</b>		<b>3,413,052,320</b>	<b>1,883,561,131</b>

Short term loan has been taken to meet up the working capital requirement and is secured by Inventories Land and Buildings.

<b>19.01</b>	LC/TR - First Security Islami Bank Limited, Gulshan Branch, Dhaka: Tk. 9,355,640			
	Opening balance		111,300,865	129,782,752
	Add: Received & interest during the year		34,976,853	173,940,620
	Less: Paid during the year		136,922,078	192,422,507
	<b>Closing Balance:</b>		<b>9,355,640</b>	<b>111,300,865</b>

Details are as under:

Limit Amount : Tk. 100,000,000  
Purpose : Import of Materials Packing materials, Spares and others items  
Security : Land & Buildings  
Interest Rate : 9% per annum  
Mode of Payment : From own sources  
Nature of Securities : Mortgage of Land & Building

<b>19.02</b>	CC (Hypo)- Janata Bank Limited, Corporate Bhaban Branch: Tk. 1,431,567,705			
	Opening balance		1,396,842,780	1,404,718,510
	Add: Received during the year		-	215,647,165
	Add: Interest during the year		148,744,094	126,877,013
	Less: Paid during the year		114,019,169	350,399,908
	<b>Closing Balance:</b>		<b>1,431,567,705</b>	<b>1,396,842,780</b>

Details are as under:

Limit Amount : Tk. 1,400,000,000  
Purpose : Meeting the requirement of working capital of the company  
Security : Inventory & Land  
Interest Rate : 9% per annum  
Mode of Payment : From own sources  
Type of Facility : CC Hypo  
Nature of Security: Mortgage of Inventory & Land

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>19.03</b>	<b>Janata Bank Ltd-WC Loan (Covid): Tk. 424,364,110</b>			
	Opening balance		-	-
	Add: Received during the year		400,000,000	-
	Add: Interest during the year		41,537,820	-
	Less: Paid during the year		17,173,710	-
	<b>Closing Balance:</b>		<b>424,364,110</b>	<b>-</b>
	Details are as under:			
	Limit Amount : Tk. 400,000,000			
	Purpose : Meeting the requirement of working capital of the company			
	Interest Rate : 4.5% upto 3rd quarter, 9% for 4th quarter.			
	Mode of Payment : From own sources			
	Type of Facility : Working Capital under Stimulus Package			
<b>19.04</b>	<b>United Commercial Bank Ltd: Tk. 320,190,742</b>			
	CC & Time Loan		150,000,000	151,362,831
	Overdraft		51,134,965	51,423,182
	UCBL- WCSP		101,000,125	-
	LATR		15,620,533	-
	UPAS		2,435,120	-
	<b>Total</b>		<b>320,190,742</b>	<b>202,786,013</b>
<b>19.05</b>	<b>Standard Chartered Bank Ltd: Tk. 6,950,852</b>			
	Overdraft		7,571,159	9,975,236
	Revolving		-	35,000,000
	Acceptance/UPAS		219,240	25,142,991
	Import Loan		(839,547)	2,513,246
	<b>Total</b>		<b>6,950,852</b>	<b>72,631,473</b>
<b>19.06</b>	<b>Easter Bank Ltd: Tk. 477,082,247</b>			
	Demand Loan		200,044,444	100,000,000
	Over Draft		204,066,812	-
	LATR		72,970,991	-
	<b>Total</b>		<b>477,082,247</b>	<b>100,000,000</b>
<b>19.07</b>	<b>Commercial Bank of Ceylon: Tk. 197,916,023</b>			
	LATR		147,916,023	-
	CBC-STL		50,000,000	-
	<b>Total</b>		<b>197,916,023</b>	<b>-</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>19.08</b>	<b>Shahjalal Islami Bank Ltd: Tk. 545,625,000</b>			
	SJIBL-Bai-Muazzal		545,625,000	-
	<b>Total</b>		<b>545,625,000</b>	<b>-</b>
<b>20.00</b>	<b>Share Application Money Refundable: Tk. 4,323,613</b>			
	Opening balance		4,323,613	4,323,613
	Payment made during the year		-	-
	<b>Closing Balance</b>		<b>4,323,613</b>	<b>4,323,613</b>
Share application money refundable amount as on 30.06.2022 was Tk. 4,323,613. The company has not paid or refund any amount during the year under audit and the balance amount remain unpaid as no claim was received during the year.				
<b>21.00</b>	<b>ACCOUNTS PAYABLE: Tk. 234,275,663</b>			
	Payable to Suppliers	Note-21.01	225,947,316	182,981,165
	Depot Expenses Payable	Note-21.02	7,687,885	14,418,261
	Others Payable	Note-21.03	640,462	18,450,237
			<b>234,275,663</b>	<b>215,849,663</b>
<b>21.01</b>	<b>Payable to Suppliers: Tk. 225,947,316</b>			
	Against Raw Materials		10,987,333	10,064,822
	Against Printing & Packaging Materials		37,654,655	8,290,808
	Against Laboratory Chemicals		12,727,918	19,754,225
	Against Computer & Accessories		8,894,925	4,757,189
	Against Plastic Items		4,111,686	9,913,716
	Against Machinery & Equipment		8,333,630	-
	Against PVC & Foil suppliers		9,094,125	2,610,980
	Against Maintenance & Service		6,430,781	5,333,647
	Against Advertising		4,944,461	(2,018,706)
	Against Promotional Items		39,635,684	27,802,351
	Against Transport & Courier		1,785,088	3,378,920
	Against Glass Item - Suppliers		(196,639)	338,740
	Against Furniture & Fixture		185,447	(475,197)
	Against Insurance Premium		37,674,984	33,264,945
	Against Misc. Suppliers		41,862,732	-
	Against Stationeries & Suppliers		1,577,895	2,333,479
	Against Electrical Equipment		97,612	-
	Construction & Engineering		-	(13,122,530)
	Spare & Parts		-	(183,540)

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Travel Agency		-	(1,267,970)
	Training & Development		145,000	(746,667)
	Sister Concern- Product Supply		-	72,951,953
	<b>Total Taka:</b>		<b>225,947,316</b>	<b>182,981,165</b>
<b>21.02</b>	<b>Depot Expenses Payable: Tk. 7,687,885</b>			
	Rangpur Depot		328,986	316,294
	Bogura Depot		386,134	371,939
	Rajshahi Depot		126,166	203,666
	Khulna Depot		525,135	399,914
	Barisal Depot		795,687	731,156
	Faridpur Depot		2,587	(150,843)
	Mymensingh Depot		363,191	441,397
	Narayangonj Depot		28,977	115,358
	Cumilla Depot		105,675	3,095,431
	Sylhet Depot		530,811	1,210,168
	Maizdee Depot		472,584	286,692
	Chittagong Depot		990,954	742,286
	Central Distribution Centre		354,354	(464,442)
	Cox's Bazar		250,540	152,169
	Mohammadpur from Dhaka North Depot		70,651	996,868
	Kakrail from Dhaka South Depot		217,754	(223,047)
	Privilege Point		205,538	146,735
	B. Baria Depot		96,440	695,418
	Feni Depot		260,219	250,012
	Jessore Depot		(28,202)	(37,485)
	Dinajpur Depot		436,161	1,298,122
	Tangail Depot		422,388	3,579,848
	Pabna Depot		166,056	373,089
	Chandpur Depot		154,368	103,406
	Niketon Depot		(108,030)	(215,890)
	Uttara Depot		532,761	-
	<b>Total Taka:</b>		<b>7,687,885</b>	<b>14,418,261</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>21.03</b>	<b>Others Payable: Tk. 640,462</b>			
	Against Motor Car		31,833,449	17,403,305
	"Gift, Cash Donation & Business Development Exp."		(13,041,131)	-
	Final Settlement of Employee		(18,685,569)	-
	Earn leave payable		268,118	666,173
	Payable Rapid Service Program		260,743	380,759
	RX Drive Day Program		4,851	-
	<b>Total Taka:</b>		<b>640,462</b>	<b>18,450,237</b>
Accounts payable for supply of raw materials, packing materials & other promotional items are the regular suppliers of the Company and the amounts are due on account.				
<b>22.00</b>	<b>ACCRUED EXPENSES: Tk. 74,299,265</b>			
	Salary & Allowances		72,518,740	95,054,376
	Gas Bills		7,231,450	3,827,115
	Audit Fees		348,000	405,000
	Credit Rating Fees		126,000	126,000
	Compliance Audit Fees		29,305	25,000
	Insurance Claim		(449,996)	850,000
	Depot Office Rent		(5,504,234)	-
	<b>Total Taka:</b>		<b>74,299,265</b>	<b>100,287,491</b>
<b>23.00</b>	<b>VAT PAYABLE: Tk. 56,668,148</b>			
	Trade Creditors		23,418,173	7,240,214
	House/Depot rent		7,180,102	3,927,856
	Audit Fees		58,000	67,500
	Credit Rating Fees		10,500	10,500
	Compliance Audit Fees		4,500	4,167
	VAT on Sales		25,996,873	-
	<b>Total Taka:</b>		<b>56,668,148</b>	<b>11,250,237</b>
<b>24.00</b>	<b>LIABILITY FOR EWF &amp; WPPF: Tk. 66,048,369</b>			
	Workers Profit Participation Fund (WPPF)	Note-24.01	66,048,369	58,577,255
	<b>Total Taka:</b>		<b>66,048,369</b>	<b>58,577,255</b>
<b>24.01</b>	<b>Workers Profit Participation Fund: Tk. 66,048,369</b>			
	Opening Balance		58,577,255	25,097,417
	Add: Contribution during the year		64,648,388	59,908,152
	<b>Total Contribution</b>		<b>123,225,643</b>	<b>85,005,569</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Less: Distributed among the employees from welfare fund		57,177,274	1,135,314
			<b>66,048,369</b>	<b>83,870,255</b>
	Less: Adjustment of Advance of Previous years to the fund		-	25,293,000
	<b>Closing Balance</b>		<b>66,048,369</b>	<b>58,577,255</b>
<b>25.00</b>	<b>LIABILITY FOR EMPLOYEES MEDICAL SUPPORT FUND: Tk. 3,052,980</b>			
	Opening Balance		-	-
	Add: Contribution during the year		3,127,070	-
	<b>Total Contribution</b>		<b>3,127,070</b>	-
	Less: Paid to the employees		74,090	-
	<b>Closing Balance</b>		<b>3,052,980</b>	-
<b>26.00</b>	<b>PROVISION FOR EMPLOYEES' PROVIDENT FUND: Tk. 30,285,304</b>			
	Opening Balance		23,003,728	46,061,080
	Addition made during the year		58,146,169	52,716,420
	<b>Total</b>		<b>81,149,897</b>	<b>98,777,500</b>
	Less: Paid to the Fund during the year		50,864,593	75,773,772
	<b>Closing Balance</b>		<b>30,285,304</b>	<b>23,003,728</b>
<b>27.00</b>	<b>PROVISION FOR GRATUITY: Tk. 105,329,468</b>			
	Opening Balance		80,309,165	55,202,000
	Addition made during the year		30,005,740	26,379,449
	<b>Total</b>		<b>110,314,905</b>	<b>81,581,449</b>
	Less: Gratuity paid during the year		4,985,437	1,272,284
	<b>Closing Balance</b>		<b>105,329,468</b>	<b>80,309,165</b>
<b>28.00</b>	<b>INCOME TAX PAYABLE: Tk. 306,111,342</b>			
	Corporate Tax Liability	Note-28.01	258,593,552	(18,646,355)
	Add: Other Tax Liability	Note-28.02	47,517,790	16,548,253
			<b>306,111,342</b>	<b>(2,098,102)</b>
<b>28.01</b>	<b>CORPORATE TAX LIABILITY : Tk. 258,593,552</b>			
	Opening Balance		(18,646,355)	(180,880,683)
	Add : Previous year tax liability up to 2020-2021.		381,604,174	
	Add: Tax provision on current year profit		258,593,552	269,586,682
	<b>Total tax liabilities as on 30.06.2022</b>		<b>621,551,371</b>	<b>88,705,999</b>
	Less: Tax paid during the period		362,957,819	
	Less: Advance Tax/AIT during the year 2021-2022		-	107,352,354
	<b>Total Corporate Tax Liability</b>		<b>258,593,552</b>	<b>(18,646,355)</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>28.02</b>	<b>OTHER TAX LIABILITY: Tk. 47,517,790</b>			
	TDS from Salary & Allowances		707,146	1,565,986
	TDS from Trade Creditors		39,978,109	13,292,942
	TDS from Sister Concern-Product Supply		1,472,584	1,132,199
	TDS from Office Rent		1,684,244	436,376
	TDS from Managing Director's Remuneration		3,458,819	-
	TDS from Gas Bills		164,259	58,971
	TDS from Audit Fee		38,629	45,001
	TDS from Compliance Audit Fee		-	2,778
	TDS Credit Rating Fee		14,000	14,000
	<b>Closing Balance</b>		<b>47,517,790</b>	<b>16,548,253</b>
<b>29.00</b>	<b>DIVIDEND PAYABLE: Tk. 164,671,640</b>			
	Opening Balance		191,702,535	112,520,500
	Add: Addition during the Year		346,500,000	138,600,000
			538,202,535	251,120,500
	Less: Dividend paid during the year		373,530,895	59,417,965
	<b>Closing Balance</b>		<b>164,671,640</b>	<b>191,702,535</b>
<b>30.00</b>	<b>TURNOVER: Tk. 8,022,736,306</b>			
	Local Sales		8,022,736,306	7,121,152,785
	Export Sales		-	-
	<b>Net Turnover</b>		<b>8,022,736,306</b>	<b>7,121,152,785</b>

Details of Turnover are as under:

Product Group	Box/Pack	Net Sales	Box/Pack	Net Sales
	30 June 2022		30 June 2021	
Injection	5,317,315	2,007,074,398	3,826,823	1,444,473,165
Tablet	11,241,364	4,002,618,705	9,149,423	3,257,758,833
Pre-Filled Syringe	64,565	1,887,799	421,324	202,930,846
Infusion	531,333	129,790,574	888,790	196,917,389
Capsule	2,217,991	908,948,271	1,705,097	698,760,636
Syrup	4,437,807	844,749,349	3,103,795	590,816,290
PFS	508,628	101,509,077	3,087,894	616,264,495
Spray	403,132	25,006,380	1,808,060	112,154,459
Cream	340	719,318	298	595,053
Gel	237	432,435	292	481,619
<b>Total</b>	<b>24,722,711</b>	<b>8,022,736,306</b>	<b>23,991,796</b>	<b>7,121,152,785</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>31.00</b>	<b>COST OF GOODS SOLD: Tk. 3,875,791,274</b>			
	Materials Consumed	Note-31.01	2,706,130,843	2,631,199,473
	Factory Overhead	Note-31.02	1,141,510,942	971,693,774
	<b>Total Manufacturing Cost</b>		<b>3,847,641,785</b>	<b>3,602,893,247</b>
	Add: Opening Work-in-Process		259,080,944	171,497,776
	<b>Total Work-in-Process</b>		<b>4,106,722,729</b>	<b>3,774,391,023</b>
	Less: Closing Work-in-Process		224,693,855	259,080,944
	<b>Cost of Production</b>		<b>3,882,028,874</b>	<b>3,515,310,079</b>
	Add: Opening Finished Goods		442,677,763	361,790,217
	Add: Finished Goods Purchased		202,928,388	-
	<b>Finished Goods available for Sale</b>		<b>4,527,635,025</b>	<b>3,877,100,296</b>
	Less: Closing Finished Goods		651,843,751	442,677,763
	<b>Cost of Goods Sold</b>		<b>3,875,791,274</b>	<b>3,434,422,533</b>
<b>31.01</b>	<b>Materials Consumed: Tk. 2,706,130,843</b>			
	Opening Inventory		439,173,665	385,340,693
	Add: Purchase		3,184,359,909	2,685,032,445
	<b>Materials available for use</b>		<b>3,623,533,574</b>	<b>3,070,373,138</b>
	Less: Closing Inventory		917,402,731	439,173,665
	<b>Total</b>		<b>2,706,130,843</b>	<b>2,631,199,473</b>
<b>31.02</b>	<b>Factory Overhead: Tk. 1,141,510,942</b>			
	Salaries & Allowances		280,313,182	245,470,446
	Co's Contribution to P.F		4,557,272	4,254,112
	Gratuity		5,237,488	4,086,894
	Local Travel & Conveyance		378,931	285,180
	Foreign Traveling Expenses		215,233	-
	Re-Agent & Other Consumption		2,184,008	-
	Entertainment		1,144,045	3,125,353
	Employee Fooding		53,436,601	37,844,080
	Employees Pick & Drop		18,430,640	14,895,743
	Day Celebration		1,541,850	-
	Employee Medical Expense		117,265	-
	Employee Welfare & Recreation		2,491,554	-
	Telephone, Fax, Courier & Internet		6,516,147	3,706,322
	Utilities		119,476,174	125,238,406
	Fees & Renewals		5,091,728	527,850
	Books, News Paper & Periodicals		284,376	375,776
	Uniform, Laundry & Cleaning		7,981,088	-

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Printing & Stationery		26,689,890	26,646,980
	Legal & Consultancy Fees		2,485,963	1,645,785
	Insurance Premium		3,197,231	5,026,333
	Handling & Carrying Expense		1,094,517	920,164
	Research & Development Expense		9,238,100	4,822,621
	Repairs & Maintenance		182,704,676	124,674,278
	Training Expense		1,166,761	537,554
	Advertisement & Publicity		220,430	34,650
	Misc. Expenses		2,114,984	2,936,145
	Toll Manufacturing Expense		1,561,148	14,147,147
	Corporate Social Responsibility (CSR)		1,512,500	-
	Depreciation		400,127,160	350,491,955
	<b>Total</b>		<b>1,141,510,942</b>	<b>971,693,774</b>
<b>32.00</b>	<b>Administrative Expenses: Tk. 465,375,613</b>			
	Salaries & Allowances		186,238,172	184,240,564
	Co's Contribution to P.F		3,150,421	2,977,333
	Co's contribution to Employee Medical Support		1,563,535	-
	Employee Medical Expense		1,311,262	-
	Gratuity		3,378,721	2,716,685
	Employee Welfare & Recreation		3,399,417	-
	Local Travel & Conveyance		3,738,105	2,132,287
	Foreign Traveling Expenses		2,810,788	295,000
	Entertainment		22,426,093	11,141,556
	Employee Fooding		38,338,269	38,845,073
	Office Rent		19,384,136	17,862,531
	Employees Pick & Drop		34,638,140	31,686,757
	Uniform, Laundry & Cleaning		2,254,310	-
	Day Celebration		1,913,669	-
	Utilities		10,616,765	7,722,040
	Telephone, Fax, Courier & Internet		9,491,427	5,599,278
	Fees & Renewals		5,351,497	1,797,431
	Books, News Paper & Periodicals		77,765	70,540
	Courier & Others		6,003,388	-
	Printing & Stationery		27,251,727	14,578,051
	Audit Fee		708,333	511,112
	Legal & Consultancy Fees		3,667,135	1,598,533
	Insurance Premium		4,428,851	4,231,919
	Bank Charge & Others		4,234,970	2,547,062

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Company Secretarial & Share Exe.		5,285,866	228,832
	Handling & Carrying Expense		192,092	231,800
	Repairs & Maintenance		22,107,578	9,340,673
	Advertisement & Publicity		7,240,707	4,042,384
	Training Expense		1,207,643	399,415
	Misc. Expenses		7,156,567	12,995,552
	Corporate Social Responsibility (CSR)		8,220,257	-
	Depreciation		17,588,007	15,406,240
	<b>Total</b>		<b>465,375,613</b>	<b>373,198,648</b>

Salaries and allowances increased due to the increase of the numbers of employees and increment as well.

<b>33.00</b>	<b>Marketing, Selling &amp; Distribution Expenses: Tk. 1,999,659,878</b>			
	Salaries & Allowances		990,691,569	991,833,404
	Co's Contribution to P.F		21,146,963	19,100,526
	Gratuity		21,389,531	19,575,870
	Employee Medical Expense		29,100	-
	Employee Welfare & Recreation		5,738,043	-
	Local Travel & Conveyance		45,305,630	33,110,186
	Foreign Traveling Expenses		2,099,505	-
	Entertainment		4,977,263	9,784,317
	Day Celebration		91,799	-
	Employee Fooding		39,283,764	24,891,842
	Office Rent		24,949,200	26,715,062
	Employees Pick & Drop		15,009,895	6,477,815
	Utilities		5,132,093	4,084,991
	Telephone, Fax, Courier & Internet		41,065,418	18,747,352
	Uniform, Laundry & Cleaning		2,965,235	-
	Fees & Renewals		2,666,429	1,948,138
	Books, News Paper & Periodicals		2,171,765	-
	Printing & Stationery		20,125,591	21,351,627
	Legal & Consultancy Fees		2,020,200	-
	Insurance Premium		9,236,835	6,324,666
	Bank Charge & Others		323,493	1,110,754
	Handling & Carrying Expense		65,600	129,201
	Repairs & Maintenance		8,576,569	8,688,831
	Research & Development Expense		5,184,920	4,605,397
	Field Force Expenses (TA/DA)		158,488,707	165,443,867

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Sales Incentive		103,614,244	126,087,619
	Training Expense		9,466,311	612,436
	Conference, fair and product launching		167,006,506	41,767,076
	Promotional Expense		40,912,730	35,605,764
	Advertisement & Publicity		20,121,659	13,282,308
	Distribution & Collection Expenses		173,641,242	240,587,927
	Free Sample		2,716,821	35,505,764
	Misc. Expenses		28,327,489	15,277,339
	Bad Debts		1,583,407	-
	Corporate Social Responsibility (CSR)		1,549,343	-
	Depreciation		21,985,009	19,257,800
	<b>Total</b>		<b>1,999,659,878</b>	<b>1,891,907,879</b>
<b>34.00</b>	<b>FINANCIAL EXPENSES: Tk. 339,380,959</b>			
	Interest on Long Term Loan	Note-34.01	40,667,720	47,878,486
	Interest on Short Term Loan	Note-34.02	297,296,409	130,646,617
	Bank Charge & Others	Note-34.03	1,416,831	1,978,113
	<b>Sub-Total:</b>		<b>339,380,959</b>	<b>180,503,216</b>
	Less: Interest transfer to Ereba Capsules Ltd		-	13,706,995
	<b>Total:</b>		<b>339,380,959</b>	<b>166,796,221</b>
<b>34.01</b>	<b>Interest on Long Term Loan : Tk. 40,667,720</b>			
	BRAC Bank Limited		624,197	1,968,918
	Rupali Bank Limited		40,043,523	45,909,568
	<b>Total</b>		<b>40,667,720</b>	<b>47,878,486</b>
<b>34.02</b>	<b>Interest on Short Term Loan: Tk. 297,296,409</b>			
	Janata Bank Ltd-CC(Hypo) & Working Capital		169,712,901	126,877,013
	United Commercial Bank Ltd		34,817,916	3,468,175
	Standard Chartered Bank Ltd		4,429,931	301,429
	Eastern Bank Ltd		26,606,187	-
	Shahjalal Islami Bank Ltd		45,625,000	-
	First Security Islami Bank Ltd		11,270,574	-
	Commercial Bank of Ceylon		4,833,900	-
	<b>Total</b>		<b>297,296,409</b>	<b>130,646,617</b>
<b>34.03</b>	<b>Bank Charge &amp; Others: Tk. 1,416,831</b>			
	Bank Charge & Others		1,416,831	1,978,113
	<b>Total</b>		<b>1,416,831</b>	<b>1,978,113</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
<b>35.00</b>	<b>Income From Other Sources: Tk. 15,087,567</b>			
	Interest on FDR		320,598	680,669
	Interest Received from Bank		1,678	2,563,008
	Gain on Disposal of Fixed Assets		3,038,820	
	"Income from Foreign Currency Flactuation"		504,363	-
	"Miscellaneous Revenue from Non-Listed Product"		3,703,470	-
	Others Income		4,984,817	-
	"Excess Claimed Received from Jibon Bima"		1,103,250	-
	Scrap Sales at Depot		122,812	-
	Gain on Product Return		1,307,760	-
	<b>Total</b>		<b>15,087,567</b>	<b>3,243,677</b>
<b>36.00</b>	<b>Contribution to Workers Profit Participation Fund: Tk. 64,648,388</b>			
	WPPF Fund contribution during the year		64,648,388	59,908,152
	<b>Total</b>		<b>64,648,388</b>	<b>59,908,152</b>
<b>36.01</b>	<b>As per provision of Section 234 of the Bangladesh Labor Law 2006 as amended, 5% of net profit before tax is contributed to the above fund in the following proportions:</b>			
	<b>Particulars</b>	<b>Proportion</b>	<b>30 June 2022</b>	<b>30 June 2021</b>
	Contribution to Participatory Fund	80%	51,718,710	47,926,522
	Contribution to Welfare Fund	10%	6,464,839	5,990,815
	Contribution to WWFF	10%	6,464,839	5,990,815
	<b>Total Taka</b>		<b>64,648,388</b>	<b>59,908,152</b>
<b>37.00</b>	<b>Unrealized (Loss)/gain on Quoted Shares : Tk. 248,025</b>			
	Unrealized Gain Realized		-	-
	Unrealized (loss)/gain during the year		151,403	248,025
	<b>Total Taka:</b>		<b>151,403</b>	<b>248,025</b>
<b>38.00</b>	<b>EARNINGS PER SHARE (EPS): Tk. 4.05</b>			
	<b>Basic Earnings per Share</b>			
	Breakup of the above amount is given below:			
	Net Profit after Tax during the year		935,036,130	863,169,294
	Weighted average number of shares during the year	Note-14.00	231,000,000	231,000,000
	<b>Earning Per Share (par value Tk. 10 each)</b>		<b>4.05</b>	<b>3.74</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

**39.00 Payment to Managing Directors: Tk. 25,200,000**

The aggregate amount paid (except Directors fees for attending board meetings) during the year to the director of the company is given below as per requirement of Securities and Exchange Rules 1987.

Particulars	2021-22	2020-21
Basic Remuneration	7,200,000	7,200,000
House Rent	3,600,000	3,600,000
Medical allowance	1,800,000	1,800,000
Conveyance	1,800,000	1,800,000
Other allowances	9,600,000	9,600,000
Bonus	1,200,000	1,200,000
<b>Total</b>	<b>25,200,000</b>	<b>25,200,000</b>

**40.00 Claims Against The Company Not Acknowledged As Debt:**  
None as on 30-06-2022.

**41.00 CREDIT FACILITIES NOT AVAILED:**

There is no credit facility available to the Company that was not availed as on 30-06-2022 under any contract, other than those mentioned in the financial statements arising in the ordinary course of business.

**42.00 DISCLOSURES AS PER REQUIREMENT OF SCHEDULE XI, PART OF THE COMPANIES ACT, 1994:**  
Total 3,531 number of Employees Drawing Remuneration is as follows:

Particulars	30 June 2022	30 June 2021
No. of Employees Having Salary Between Tk. 4,000 to Tk. 5,000	-	-
No. of Employees Having Salary Between Tk. 5,000 to Tk. 10,000	264	522
No. of Employees Having Salary Between Tk. 10,000 to Tk. 15,000	661	679
No. of Employees Having Salary Between Tk. 15,000 to Tk. 25,000	1,178	1,231
No. of Employees Having Salary Between Tk. 25,000 to Tk. 50,000	1,128	872
No. of Employees Having Salary Between Tk. 50,000 and above	303	227
<b>Total:</b>	<b>3,534</b>	<b>3,531</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

**43.00 CAPACITY UTILIZATION:**

Production capacity and current utilization as required by the companies Act 1994, Schedule-XI, Para-7. Actual production and utilization for major products groups are as follows:

Major product/Unit	Capacity (In Millions)	30 June 2022		30 June 2021	
		Actual Production (In Millions)	Utilization (%)	Actual Production (In Millions)	Utilization (%)
Tablets	2,520	2,318	92%	2,268	90%
Capsules (Filled with Pellets)	760	684	90%	669	88%
Capsules (Filled with Powder)	850	748	88%	723	85%
Powder for suspension(Bottles)	15	13	86%	13	85%
Injection (Ampoules)	10	9	86%	9	85%
Injection (Lyophilized))	9	8	89%	8	88%
Large Volume Parenteral	4	4	91%	4	90%
Pre-filled Syringe	4	4	89%	4	88%
<b>Total:</b>	<b>4,172</b>	<b>3,787</b>		<b>3,696</b>	

**44.00 Net Operating Cash Flows Per Share (Nocfps):**

Cash flows from operating activities as per Statement of cash flows		1,079,846,584	196,557,471
Weighted average number of shares during the year (Note-14.00)		231,000,000	231,000,000
Net Operating Cash Flows per Share (par value Tk. 10 each):		<b>4.67</b>	<b>0.85</b>

**45.00 Reconciliation of Net Profit with Cash Flows from Operating Activities making adjustment for Non-cash items, for Non-operating items and for the Net changes in operating Activities:**

<b>Profit after Tax during the year</b>	<b>935,036,130</b>	<b>863,169,294</b>
Adjustment to reconcile Net Profit to Net Cash Provided by Operating Activities:		
<b>Non-Cash Expenses</b>	<b>539,038,255</b>	<b>450,563,048</b>
Depreciation	439,700,176	385,155,994
Deferred Tax	99,338,078	65,407,054
<b>Non-operating items:</b>	<b>339,380,959</b>	<b>10,463,318</b>
Interest Income	-	10,463,318
Interest Expenses	339,380,959	
<b>Changes in Working Capital:</b>	<b>(793,535,603)</b>	<b>(1,185,079,758)</b>
(Increase)/Decrease in Inventory	(693,283,074)	(246,065,883)
(Increase)/Decrease in Trade Debtors	(30,716,760)	(873,780,659)
(Increase)/Decrease in Advances , Deposits & Prepayments	108,136,970	(411,001,891)
(Increase)/Decrease in Income Tax	(169,844,198)	162,234,328

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021
	Increase/(Decrease) in Trade Creditors		(7,828,540)	183,534,347
	(Increase)/Decrease in Liabilities for Expenses & Others:		<b>62,255,658</b>	<b>57,441,569</b>
	Increase/(Decrease) in Accrued Expenses		(25,988,226)	21,948,778
	Increase/(Decrease) in VAT Payable		45,417,911	(36,860)
	Increase/(Decrease) in Liabilities for EWF & WPPF		7,471,114	(23,057,352)
	Increase/(Decrease) in Employees Medical Support Fund		3,052,980	
	Increase/(Decrease) in PF		7,281,576	-
	Increase/(Decrease) in Gratuity		25,020,303	58,587,003
	<b>Net Cash Generated from Operating Activities</b>		<b>1,082,175,400</b>	<b>196,557,471</b>
<b>46.00</b>	<b>NET ASSETS VALUE PER SHARE (NAV):</b>			
	Total Shareholders' Equity		5,943,850,486	5,355,162,953
	Weighted average number of shares during the year	(Note-14.00)	231,000,000	231,000,000
	<b>Net Assets Value per Share (par value Tk. 10 each)</b>		<b>25.73</b>	<b>23.18</b>
<b>47.00</b>	<b>RECONCILIATION OF EFFECTIVE TAX RATE:</b>			
			"Amount in Taka"	%
	<b>Profit Before Tax</b>		<b>1,292,967,761</b>	
	Regular tax rate of the company		258,593,552	20.00%
	Non-Deductible Expense		-	0.00%
	Effect of tax exempted income		-	0.00%
	Effect of lower tax rate		-	0.00%
	Effect of deferred tax on temporary difference		99,338,078	7.68%
			<b>357,931,630</b>	<b>27.68%</b>

**Beacon Pharmaceuticals Limited**  
**Notes to the Financial Statements**  
**For the year ended 30 June 2022**

Notes Sl. No.	Particulars	Notes	Amount in Taka	
			30 June 2022	30 June 2021

**48.00 RELATED PARTY DISCLOSURE:**

During the year the company carried out a number of transaction with related parties in the normal course of business on an arm's length basis. Name of those related parties, nature of those transaction and their total value has been shown in the below table in accordance with IAS-24 " Related Party disclosures.

Name of the Parties	Relationship	Nature of Transaction	Opening Balance	Addition	Adjustment	Closing Balance
Beacon Medicare Limited	Customer	Trade Receivables	1,336,690,992	1,154,786,958	1,066,220,699	1,425,257,251
Ereba Capsule Limited	Related Party	Intercompany Loan	403,706,995	148,093,005	500,000,000	51,800,000
Beacon Cephalosporine Limited	Suppliers	Trade Payable	(54,903,283)	425,855,236	194,091,464	176,860,489
Beacon Business Soluation Limited	Suppliers	Trade Payable	(18,048,670)	-	6,344,743	(24,393,413)
Beacon Business Soluation Limited	Related Party	Intercompany Loan	-	12,722,136	-	12,722,136
Beacon Medicare Limited	Related Party	Intercompany Loan	-	265,688,267	-	265,688,267
Beacon Cephalosporin Limited	Related Party	Intercompany Loan	-	66,091,735	2,260,295	63,831,440
Beacon Nutraceuticals Limited	Related Party	Intercompany Loan	-	22,702,611	-	22,702,611
MEK Pharmatech Limited	Related Party	Intercompany Loan	-	22,272,000	-	22,272,000
MEK Auto Bricks Limited	Related Party	Intercompany Loan	-	7,609,400	-	7,609,400
Beacon Oncology Limited	Related Party	Intercompany Loan	-	52,603,166	5,000,000	47,603,166
Beacon Power System Limited	Related Party	Intercompany Loan	-	38,349,750	10,348,650	28,001,100
<b>Total</b>			<b>1,336,690,992</b>	<b>2,095,939,948</b>	<b>1,768,917,201</b>	<b>1,994,468,781</b>

"Beacon Medicare Limited is a sister concern as well as a customer of **Beacon Pharmaceuticals Limited** So the amount has been disclosed in related party transaction as well as in accounts receivable. (Ref. Note-08.00 under Accounts Receivable)."

**49.00 EVENT AFTER THE REPORTING PERIOD:**


The Board of Directors in its meeting held on 25 October 2022 has commended 16% (Sixteen Percent) Cash dividend for the year ended 30 June 2022 subject to approval of the shareholders at the ensuing Annual General Meeting (AGM).

**50.00 CONTINGENT LIABILITIES:**

There may arise tax liability on final assessment of tax remain pending with taxation authority. Without the above, there is no known contingent liabilities.

  
 Company Secretary

  
 Managing Director

  
 Chairman

**Beacon Pharmaceuticals Limited**  
**Schedule of Fixed Assets**  
**For the year ended 30 June 2022**

Annexure-A

Particulars	COST				Rate of Dep. (%)	DEPRECIATION				Written Down Value as on 30.06.22
	Balance as on 01.07.2021	Addition during the year	Adjustment during the year	Balance as on 30.06.2022		Depreciation as on 01.07.2021	Charged during the year	Adjustment during the year	Depreciation as on 30.06.2022	
Land & Land Development	566,064,574	58,037,728	-	624,102,302	-	-	-	-	-	624,102,302
Factory Building	917,954,184	-	-	917,954,184	5%	399,109,464	45,897,709	-	445,007,173	472,947,011
Corporate Head Office Building	60,456,584	-	-	60,456,584	5%	12,105,787	3,022,829	-	15,128,616	45,327,968
Vehicles	309,967,233	182,728,150	11,617,000	481,078,383	20%	175,300,795	70,180,320	5,808,500	239,672,615	241,405,768
Electrical Installations	185,068,855	15,364,478	-	200,433,333	10%	84,569,355	18,839,933	-	103,409,288	97,024,045
Office Equipment	162,928,238	75,610,504	343,820	238,194,922	10%	75,438,772	17,851,118	105,915	93,183,975	145,010,947
Production Machinery & Equip.	1,627,020,538	286,451,642	433,088	1,913,039,092	15%	297,280,304	265,555,245	433,088	562,402,461	1,350,636,631
Furniture & Fixture	180,144,262	17,966,123	-	198,110,385	10%	84,114,704	18,353,021	-	102,467,725	95,642,660
<b>Total Taka:</b>	<b>4,009,604,468</b>	<b>636,158,626</b>	<b>12,393,908</b>	<b>4,633,369,186</b>		<b>1,127,919,181</b>	<b>439,700,176</b>	<b>6,347,503</b>	<b>1,561,271,854</b>	<b>3,072,097,332</b>

Allocation of Depreciation	Proportion	Amount(Tk.)
Factory Overhead	91%	400,127,160
Administrative Overhead	4%	17,588,007
Selling, Marketing Expenses	5%	21,985,009
<b>Total Taka:</b>	<b>100%</b>	<b>439,700,176</b>

**Beacon Pharmaceuticals Limited**  
**Deferred Tax Schedule**  
**For the year ended 30 June 2022**

Annexure-B

Particulars	COST			DEPRECIATION			Tax Base as on 30.06.2022
	Tax Base as on 01.07.2021	Addition during the year	Adjustment during the year	Balance as on 30.06.2022	Rate as per 3rd Schedule (%)	Addition during the year	Charged during the year
Factory Building	196,798,838	-	-	196,798,838	10%		19,679,884
Corporate Head Office Building	58,507,050	-	-	58,507,050	5%		2,925,353
Vehicles	155,682,892	182,728,150	11,617,000	326,794,042	20%		65,358,808
Electrical Installations	118,323,373	15,364,478	-	133,687,851	10%		13,368,785
Office Equipment	103,752,838	75,610,504	343,820	179,019,522	10%		17,901,952
Production Machinery & Equipment	606,706,093	286,451,642	433,088	892,724,647	20%		178,544,929
Furniture & Fixture	114,728,147	17,966,123	-	132,694,270	10%		13,269,427
<b>Total</b>	<b>1,354,499,231</b>	<b>578,120,897</b>	<b>12,393,908</b>	<b>1,920,226,220</b>		<b>-</b>	<b>311,049,138</b>
							<b>1,609,177,082</b>

**Deferred Tax Calculation:**

Description	Carrying amount of Balance sheet as on 30th June, 2022	Tax Base	Taxable/ (deductible) temporary difference
Fixed Assets (Excluding Land & Land Development)	2,447,995,029	1,609,177,082	838,817,947
Gratuity Provision	(105,329,468)	-	(105,329,468)
Provision for Provident Fund	(30,285,304)	-	(30,285,304)
Taxable /(deductible) temporary difference			703,203,175
Tax Rate			20.00%
Deferred Tax (Assets)/Liability at end of the year			140,640,635
Deferred Tax (Assets)/Liability at biggining of the year			239,978,713
Change in Deferred tax (income)/expenses			(99,338,078)
<b>Deferred Tax charged to Profit or Loss and other comprehensive income:</b>			<b>(99,338,078)</b>

**Corporate Office:**

BEACON Business Centre  
9/B/2 Toyenbee Circular Road (Box Culvert Road),  
Motijheel C/A, Dhaka-1223, Bangladesh.  
Tel : +880-2-57165371-76, Fax : +880-2-57165379  
E-mail : beacon@beaconpharma.com.bd  
Website : www.beaconpharma.com.bd

## NOTICE OF 21<sup>ST</sup> ANNUAL GENERAL MEETING

Notice is hereby given that the 21<sup>st</sup> Annual General Meeting of **Beacon Pharmaceuticals Limited** will be held on Tuesday, 27 December 2022 at 11.00 am by using Digital Platform to transact the following business:

### AGENDA

**Ordinary Business:**

1. To receive and adopt the Directors' and Auditors' Report and the Audited Financial Statements of the Company for the year ended 30 June 2022.
2. To declare dividend for the year ended 30 June 2022.
3. To elect/re-elect Directors under rotation.
4. To approve the appointment of Independent Director.
5. To appoint Statutory Auditors for the year 2022-2023 and to fix their remuneration.
6. To appoint Corporate Governance Compliance Auditors for the year 2022-2023 and to fix their remuneration.

**Special Business:**

**To consider and if thought fit pass the following resolution as a Special Resolution.**

1. RESOLVED THAT Articles 118 of the Articles of Association of the Company be deleted and the following be substituted in its place:  
"118. The remuneration of a Director other than salaried Directors for attending Board / Committee meetings shall be decided by the Board of Directors from time to time."
2. RESOLVED THAT the name of the company be and is hereby changed to "Beacon Pharmaceuticals PLC." from "**Beacon Pharmaceuticals Limited**" as per provision of the Companies (2<sup>nd</sup> Amendment 2020) Act, 1994."  
"FURTHER RESOLVED THAT the old name of the company will be replaced by the new name in all the statutory/title documents, licenses and other relevant documents for which no further approval from shareholders or directors will not be required".

By Order of the Board



**Khalilur Rahman FCS**  
Company Secretary (Acting)  
05 December 2022

**Registered Office:**

**Beacon Pharmaceuticals Limited**  
Kathali, Bhaluka, Mymensingh, Bangladesh.

**Corporate Office:**

BEACON Business Centre  
9/B/2 Toyenbee Circular Road (Box Culvert Road),  
Motijheel C/A, Dhaka-1223, Bangladesh.  
Tel : +880-2-57165371-76, Fax : +880-2-57165379  
E-mail : [beacon@beaconpharma.com.bd](mailto:beacon@beaconpharma.com.bd)  
Website : [www.beaconpharma.com.bd](http://www.beaconpharma.com.bd)

**Notes:**

1. The Record date of The Company shall be the Thursday, 17 November 2022. Members whose names appeared in the Depository/ Members Register on the Record Date will be eligible to join the meeting and will qualify for Dividend.
2. Members entitled to attend and vote at the Annual General Meeting may appoint Proxy to attend and vote on their stead. The Proxy Form must be affixed with the requisite revenue stamp (BDT. 20.00) and must be submitted to the Corporate Office of the company or e-mailed to [mohibur-acc@beaconpharma.com.bd](mailto:mohibur-acc@beaconpharma.com.bd) not less than 48 hours before the time fixed for the Annual General Meeting.
3. The soft copy of the Annual Report 2022, Proxy Form and Notice of 21<sup>st</sup> AGM of the Company will be sent to all the Members' respective e-mail addresses as is available in the Beneficiary Owner (BO) account on the Record date. The soft copy of the Annual Report-2022 will also be available at the Company's website at [www.beaconpharma.com.bd](http://www.beaconpharma.com.bd).
4. Members are requested to update their BO ID contact information i.e., address, mobile no, email address, bank account information through their concerned DP.
5. AGM joining procedure will be notified later through e-mail/SMS/website of the Company in due course.

**Attention: As per BSEC Guidelines, the Shareholders shall not be entertained with any gift/food item in the ensuing AGM.**

## Photos of 20<sup>th</sup> Annual General Meeting





## NOTES



## PROXY FORM

I/We .....

Of .....

being a member of **Beacon Pharmaceuticals Limited** hereby appoint.

Mr./ Mrs./ Ms .....

Of ..... as my proxy in my/our absence to attend and vote for me/us on behalf of the 21<sup>st</sup> Annual General Meeting of the company to be held on Tuesday, 27 December, 2022 at 11.00 a.m. through Digital Platform (in pursuant to the Bangladesh Securities and Exchange Commission's order no. SEC/SRMIC/94-231/25; dated: 08 July 2020) and at any adjournment thereof.

As witness my hand this ..... Day of 27 December 2022

Signature of Proxy .....

Signature of Member .....

BO ID of Member 



#### **Corporate Office**

**BEACON Business Centre**

9/B/2, Toyenbee Circular Road

Motijheel C/A, Dhaka-1223, Bangladesh

E-mail : [beacon@beaconpharma.com.bd](mailto:beacon@beaconpharma.com.bd)

Website : [www.beaconpharma.com.bd](http://www.beaconpharma.com.bd)